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5Foreword
When talking about illicit drug use, it is important to remember that this term is
a convenient ‘shorthand’ for a range of complex behaviours. Different drugs are
used in different ways and in different combinations. And as patterns of drug use
develop and change over time, so do the implications of drug use for public health.
Successful prevention, treatment and harm-reduction interventions require a sound
understanding of the nature and extent of the drug problem, as do interdiction
and other supply reduction measures. Monitoring trends in drug use and accessing
overall consumption levels is therefore a critical requirement for the development
and targeting of effective interventions of every kind.
Although understanding patterns and trends in drug consumption is an important
goal, it is also a methodologically challenging one. Drug use presents us with both
a moving target and one that is difﬁcult to observe. New patterns of drug use can
become established in a short time, and sometimes develop into major problems before
they have even been widely identiﬁed. The problems of measuring what is often a
highly stigmatised and hidden behaviour are a key concern of the scientiﬁc literature
in this area, and wrestling with these issues forms a central component of much of the
work of the EMCDDA. In this area, no single measure provides a full picture of the
drug situation, and the overall strategy has been to adopt a multi-indicator approach.
Speciﬁc information sources have been developed to highlight particular aspects of
the phenomenon, and by putting these together, a more comprehensive analysis can
be built up. Surveys, for instance, provide an important window on some types of
drug use, but need to be complemented with targeted studies and statistical modelling
if a more comprehensive picture is to be produced. Considerable progress has been
made in improving methods in all these areas, ranging from more sophisticated
statistical models to the use of computer-aided interviews to reduce respondent bias.
Nonetheless, sampling problems and response bias remain major problems for survey
techniques, and indirect modelling of the unknown population from the observable
population is both complicated to achieve and requires at least a proportion of the
population of interest to be observable in some fashion. A common problem of all
methods in this area is that, as they are often time-consuming and complex, they often
require considerable resources to be invested if they are to produce satisfactory results.
In this report, we explore both the potential use and the likely limitations of a
new and novel approach to monitoring the use of illicit drugs. This approach has
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6
been made possible by recent improvements that have increased the sensitivity of
analytical laboratory equipment. Developments in chromatographic and
mass-spectrometric analysis have made it possible to identify urinary excretion
of illicit drugs and their main metabolites in wastewater at very low concentrations.
The initial focus of work in this area was on the monitoring of environmental
contamination caused by the excretion of prescription medicines. However,
it was quickly realised that these approaches might lead to the possibility of
assessing levels of illicit drug use by detecting their residues in the environment.
While work in this area is in its infancy, the approach itself appears increasingly
promising. It is becoming clear that new developments in our ability to detect drugs
and their metabolites in wastewater are likely to have important implications for
the approaches we adopt to monitoring drug consumption trends over time. On a
practical level, this approach raises a number of important technical and ethical
issues. With these considerations in mind, in April 2007, the EMCDDA hosted a
technical meeting to stimulate a dialogue between drug epidemiologists and those
working in this new ﬁeld on how best to integrate this new approach into current
research thinking. The results of this meeting are summarised in this edition of
the EMCDDA Insights series, which I feel will make an important contribution to
the debate on future approaches to drug use monitoring in Europe.
Wolfgang Götz
Director of the EMCDDA
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Chapter 1: Introduction to sewage
epidemiology and the wastewater system
Norbert Frost and Paul Grifﬁths
Wastewater analysis
Human societies produce many kinds of waste products. Even where relatively
sophisticated methods of disposal are available, there always remain some residues,
which in one way or another are returned to the environment. At a time when
there is a growing awareness of what our societies introduce into the environment,
the reliable detection of potential ecological threats or health damage due
to environmental agents has become an important issue. Measures to detect such
potential threats are being included in the continuous monitoring of the environment
that is becoming increasingly common in many Member States.
The environmental fate of therapeutic drugs has been increasingly recognised
worldwide as an important issue. Concern about this issue was one of the factors
that provided an initial impetus to work in the area of wastewater analysis through
the monitoring of environmental contamination caused by prescribed drugs,
and the related question of the effectiveness of water treatment plants. An
example of this is the work conducted in Germany during the 1990s in which
investigations were carried out into the extent that therapeutic drugs were
detectable in rivers and wastewater systems (Ternes, 1998; Ternes et al., 1999).
The main concern of this environmental monitoring was the extent to which a
known level of drug prescription was likely to produce residues that were excreted
into the environment.
Following on from the earlier work to monitor for the presence of therapeutic
drugs in wastewater samples, it became clear that it might also be possible to use
the same methodology to assess levels of illicit drug use by detecting their residues
in the environment. One of the ﬁrst suggestions that it might be possible to use
the results of analyses conducted on wastewater samples taken from sewage
treatment facilities to determine illicit drug use within communities was made by
Daughton (2001). Illicit drug use is, by its nature, a covert and hidden activity,
and traditional survey methods (such as population or household surveys) can
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be inefﬁcient and sometimes ineffective ways of estimating levels of at least some
types of illicit drug use.
The possibility that a new technique for estimating illicit drug use might be added to
the existing repertoire of research methods was, therefore, an exciting prospect.
As the sensitivity and accuracy of analytical equipment and methods have
improved during the past 30 years, so have the capacities for the detection of
substance use. Recent technological advances have increased the sensitivity of
chromatographic and mass-spectrometric analysis. These developments have made it
possible to identify urinary excretion of illicit drugs and their main metabolites
in wastewater at very low concentrations (Castiglioni et al., 2006). This is
comparable to taking a much diluted urine sample from an entire community
(rather than from an individual user). When monitoring for drugs, wastewater
analysis depends on the mass ﬂow of the substance detected. Using wastewater as
a matrix, the residues of therapeutic drugs or illicit drugs that have been released
into the sewage system can be separated in chromatograms. This may include the
possibility of computing the mass balances of substances in order to back-calculate
levels of overall drug consumption.
When making back-calculations of drug consumption based upon the mass ﬂow
of metabolites, surface water samples cannot be considered to be a matrix of
choice due to their vulnerability to confounding inﬂuences from large numbers
of unpredictable variables. Surface water analysis in the neighbourhood of a
wastewater treatment plant’s outlet (efﬂuent) may, however, provide a means to
assess the effectiveness of the treatment plant. For drug monitoring purposes,
sampling in the main proximal inﬂuent to the wastewater treatment plant may be
both opportune and recommended.
A crucial component in the management of communal waste is the wastewater
system in general, and the wastewater treatment plant in particular. Wastewater
systems differ from each other, as do the communities they serve. Beyond knowing
what may happen to drug residues while they are in the wastewater, interpretation
of the analytical data will depend on the answer to the key question ‘what is
happening to drug residues in this wastewater system?’ It is clear that developing
an approach to monitoring community drug use based on wastewater analysis
will be a multidisciplinary endeavour involving ﬁelds as diverse as system theory,
non-linear dynamics and spatial epidemiology.
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The content of this publication
This document presents a number of contributions that relate to what is becoming
known as ‘wastewater sampling for drugs’, ‘drug wastewater analysis’, or ‘drug
sewage epidemiology’. This area of work is developing in a multidisciplinary
fashion, and contributions to our understanding of the topic are being made by
scientists working in different research areas. For this reason, the contributions to
this document come from a variety of different perspectives. Analytical chemistry
has traditionally been the science most closely involved in this type of work.
More recently, within environmental toxicology, a specialty has developed that
is concerned with the surveillance, detection and quantiﬁcation of drug residues
whether these were legally or illegally introduced into the environment. In the present
document there are important contributions from the perspectives of analytical
chemistry, physiology and biochemistry, sewage engineering, spatial epidemiology
and statistics, and conventional drug epidemiology.
The chapter on estimating community drug use by Ettore Zuccato and colleagues at
the Istituto di Ricerche Farmacologiche ‘Mario Negri’, in Milan, provides an overview
of the procedures used to estimate drug consumption rates in communities by
analysis of wastewater. The method is based on the measurement of the breakdown
Figure 1: Wastewater treatment plant Münster (North Rhine-Westphalia), Germany, provided
by Stadt Münster, Städt. Tiefbauamt.
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products of illicit substances collectively excreted with the urine by consumers
and conveyed to the treatment plants with the wastewater. When pharmacokinetic
and metabolic factors and the environmental fate of excretion products are taken
into account, the environmental loads of a drug and its metabolites can be used as
indicators of consumption.
This ‘sewage epidemiology’ approach investigates mass ﬂows of the urinary
breakdown products of illicit drugs to estimate epidemiological data, i.e. drug
consumption rates in the population. However, among the important points made
by Zuccato and colleagues are that the ‘sewage epidemiology’ approach may be
able to provide objective data of drug consumption in real time, but it also carries
with it several potential sources of uncertainty that may compromise the accuracy of
subsequent consumption estimates. Despite its limitations, the authors conclude that
this approach may have speciﬁc value in proﬁling drug consumption in real time,
where ofﬁcial methods are lacking, and in monitoring changing trends (see Zuccato,
in press, for a discussion on this topic).
The chapter by Teresa Summavielle presents an overview of the metabolic
pathways of two different substances and their intracorporal degradation before
reaching the wastewater system. The chapter considers some of the factors that
may occur at the individual level, prior to the excretion of drug residues into the
wastewater system.
For example, different routes of drug administration produce different blood levels
of the drug and different peak times. Although plasma concentrations are generally
proportional to the dose of the ingested drug, the ratio between ingestion and blood
level will depend on the route used. This chapter also draws attention to uncertainties
surrounding possible individual variations in the response to a set dose of drugs.
These may be affected, for example, by the age and sex of the user, by body mass,
kidney and liver function, by interaction with other drugs, previous drug use history
and genetic variability.
Jörg Rieckermann’s chapter discusses current knowledge on the transport and fate
of illicit drugs in urban drainage systems. Typically, a drainage system includes
house connections, manholes, main sewers, and retention tanks, and the system
itself is normally complemented with a wastewater treatment plant. Sewer systems
are themselves complex: mostly they have evolved over time and few of them have
been planned from scratch. The chapter considers the discharge patterns of drugs
to sewers, and a description is provided of in-sewer processes, and the relevance of
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these processes to making accurate back-calculations of usage ﬁgures is discussed.
Finally, the chapter looks at issues regarding the monitoring of drug loads over time.
As in other chapters, these issues are considered mostly in relation to cocaine, since
this is the substance for which most information is available.
The chapter by Fátima Pina considers how maps can be used by health scientists
as an important tool to understand the complex interrelationships that exist between
humans, diseases, and the environment. Maps can be used to complement other
tools of spatial statistical analysis, epidemiology and public health in order to
increase our understanding of the occurrence and localisation of health events.
Geographical information systems provide options for spatial analysis by allowing
the overlay of different maps to determine topological relationships of connectivity,
proximity and adjacency. This has particular relevance to sewage epidemiology.
For example, maps of the sewage network can be overlaid with maps containing
population distribution. Wastewater samples are taken at speciﬁc locations (exact
geographical coordinates) and can be geo-referenced. The relationships between
the sampling point, the sample itself, and its ﬁnal analytical description become
more meaningful when combined with contextual information such as population
density in the catchment areas, and demographic or socio-economic variables.
Lucas Wiessing and colleagues consider how data from wastewater studies might be
integrated with estimates of illicit drug use from conventional approaches.
The chapter brieﬂy reviews current methods for monitoring and estimating illicit drug
use and discusses issues that arise with regard to future work linking wastewater
measurements with prevalence estimates.
In the ﬁnal chapter, Roberto Fanelli and Norbert Frost bring together the various
contributions, and sketch out some ﬁnal conclusions and recommendations.
There is no doubt that the prospect of estimating drug loads from wastewater
measurements presents an attractive proposition. In the various chapters, it
becomes clear that this interesting new approach is accompanied by a number
of uncertainties. There are various factors that may have important, but currently,
poorly understood effects upon the ﬁndings and their interpretation. These issues
are themselves interesting and further research will undoubtedly be required
to enable a better understanding of the utility of this approach and of the best
interpretation of the results.
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Areas of uncertainty
Undoubtedly, there are difﬁculties in using wastewater measures of drugs to make
inferences about the prevalence of users. The approach may, for example, be
subject to limitations in the accuracy of estimates regarding collective consumption
parameters, and these levels of uncertainty might be further increased by potential
sources of error and variability related to the assumptions that are required for
the calculations.
Uncertainties surrounding the analysis of wastewater samples may include, for
example, issues concerning epidemiological questions, such as the phenotypes
of users or behavioural variations in patterns of drug taking. Uncertainties may
be related to individual differences in drug metabolism, such as the levels of
drug metabolites in the blood. Information on human excretion rates for different
substances is important for calculating the original amount of drugs consumed,
but the data that is available on this topic is very limited. In the case of cocaine,
the correction factors that are applied to metabolism and excretion rates tend to be
based upon average values of the percentage of cocaine dose that is excreted as
its metabolite, benzoylecgonine, and in the absence of other data, these correction
factors are applied to other types of drugs. Little evidence is available to support
or question the validity of these assumptions. Also, these values have generally been
obtained from rather small samples of healthy volunteers, and they may not be
representative of the metabolic responses of chronic drug users.
Similarly, a more precise interpretation of the results of wastewater analysis will
require further information about the mobility of the introducing population.
Closed water systems may serve transient human populations, and as a result,
it may be difﬁcult to characterise the population served by a given wastewater
treatment system because of various sorts of changes that may occur in the resident
populations of a given area (for instance, due to people congregating at inner-city
venues during weekends). This may lead to problems in determining
whether an apparent rise in observed drug use measures are due to an increase
in consumption by the resident population, or to an increase in the number of
the consumers because of changes of the resident population.
In addition, information will be required about excretion patterns and other factors
relating to the introduction of drugs and their metabolites into the wastewater
system. Variations in patterns of lavatory usage combined with the low percentages
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of users of illicit drugs (e.g. cocaine or heroin) mean that marked ﬂuctuations would
be expected in the load patterns for these illicit drugs and their metabolites.
From an environmental engineering standpoint, the back-calculation of use ﬁgures
and the monitoring of trends from illicit substance loads require an understanding of
the wastewater system and its processes. The samples obtained from a wastewater
system will be affected by leakage or heavy rainfalls. The greatest loss of drug
residues is likely to occur during storm events. The analysis of wastewater samples
may also be confounded by the sudden or unexpected introduction of high
concentrations of chemical agents. Information should be available about signiﬁcant
potential confounders such as the clinical use of different drugs and the inﬂuence
of introduced products from the pharmaceutical industry or veterinary medicine
(Heberer, 2002). Such information is required to avoid erroneous interpretations
concerning ‘illegal’ consumption.
Finally, information is required about substance transport or degradation in
wastewater systems. The physical, chemical and biological transformation processes
of solutes may have an important effect upon the ability to make meaningful
estimates, and knowledge about such processes is incomplete, even for conventional
pollutants. A number of complex chemical and biological interactions occur within
sewer systems. Very little is known about how drugs and their metabolites in
wastewater systems may be affected by biotransformation or sorption in sewer
bioﬁlms and sediments. Drug loads may also be affected by natural processes such
as changes in wastewater temperature.
The analysis of wastewater is based upon samples drawn from the total liquid waste
produced by a society. The mass ﬂow of the analytes contains information about
overall consumption. The results do not provide speciﬁc information about who has
consumed which drugs, or what speciﬁc doses of drugs may have been taken. It
is not possible to determine directly whether the observed variation in wastewater
samples is reﬂective of changes in the number of active users (prevalence), or
whether it relates to changes in levels of use (patterns of use, dosage) among users.
It is possible that wastewater measurements may be more readily applicable for
continuous monitoring of the amounts of a drug in the wastewater system. This sort
of consumption index might be used as an index of drug use for speciﬁed closed
systems (e.g. at the city level).
An interesting possibility is that wastewater analysis at the community level might
offer an innovative method for obtaining information about whether interventions
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targeting drug supply or drug demand (for instance interventions directed against
drug distributors, identiﬁcation and blocking of drug distribution, or public health
campaigns) might have achieved any effect. Again, the utility of the method for such
purposes is unproven and requires empirical investigation.
Ethical and legal aspects of wastewater sampling
In addition to the theoretical and scientiﬁc limitations, the work in this area also
raises some interesting but challenging ethical and legal questions in relation to
wastewater sampling.
Unlike surface waters, which are generally accessible to everybody and therefore
do not create any obstacle in obtaining ﬂuid samples, access to wastewater systems
is likely to be subject to certain restrictions. Often, this will be for obvious reasons
of safety and security. Generally, access to wastewater systems is restricted to the
staff that are involved in maintenance. These processing systems are usually
operated by public institutions such as community municipalities, or private
enterprises as contractors. In practice, when an external agency wants to obtain
wastewater samples, it will be necessary to obtain some form of permission from
the responsible authorities. The decision to provide or deny access will often be
taken by the operator, in accordance with the day-to-day operating rules of
the service or the municipality and any relevant national legislation or codes
of practice.
It is likely that a primary purpose of wastewater monitoring for residues of drugs
will often be to obtain an area-level proﬁle regarding concentrations of drugs. In
this case, the focus will be upon mass ﬂow and the choice of location for sample
collection is likely to be the main proximal inﬂuent to the wastewater treatment
plant. This would avoid conﬂicts with data protection issues, since the results would
be aggregated and would relate to a population and not to identiﬁable individuals.
In the case of several joint systems, one could also consider the main collectors
as sampling points, where each community discharges into the jointly used
collector sewer.
Nonetheless, an important feature of the wastewater system is that the house
connection provides the last ‘private point’ before the individual household’s waste
products are mixed with all other input. The waste products that are carried through
house-linked sewers can, therefore, be clearly identiﬁed in relation to speciﬁc
households. Individual waste from a single household, when subject to wastewater
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analysis, would allow for the identiﬁcation of illicit drug use and for the construction
of a speciﬁc, identiﬁable proﬁle of consumption patterns.
The nature of closed wastewater systems permits the selection of a speciﬁc location
as a unit of analysis. This could be, for example, the wastewater that comes directly
from a particular building, a university campus, a military establishment, a local
neighbourhood, or even a parliamentary chamber. Wastewater analysis does
not require individual consent, and may be viewed by some as representing an
unacceptable form of intrusion. There are clearly a number of potential ethical and
privacy issues that are raised by this kind of surveillance approach.
It is not difﬁcult to see that various individuals and agencies might take an interest in
being able to identify the emission of illicit drugs (or other substances) from identiﬁed
households. Information of this sort might be of interest to police, journalists or
blackmailers. At present, other than the normal operating procedures regarding
restricted access, there is little or no legal safeguard against private or state
agencies obtaining access to household waste. Taking samples directly at the level
of house connections goes beyond the scope of system monitoring and, from an
ethical perspective, cannot be recommended.
A clear distinction should be made about the purposes and extent of investigations
involving wastewater sampling: in particular, clarity is needed about whether
the ﬁndings are to be used in the interests of public health or as a part of law
enforcement or political control measures. While a monitoring programme of
main wastewater streams or wastewater treatment plant inﬂuents seeks to establish
community-wide average values, the speciﬁc sampling of public institutions or private
households will not provide public-health relevant information and therefore cannot
be recommended.
From an ethical and legal perspective, many of the apparent difﬁculties arise if this
new approach is applied for purposes other than scientiﬁc inquiry. From a purely
research perspective, ensuring the anonymity of individuals is a familiar issue that
applies to any study that generates collective data; though in this case, the issue
of informed consent may be more problematic. Standard research procedures
are generally required to provide guarantees of anonymity. The same ethical
understanding should apply to sampling in wastewater systems. However, a crucial
difference is that wastewater sampling can take place without informed consent and
users may not be given the option of not ‘participating’. It should be noted, however,
that this issue also applies to sampling for environmental monitoring purposes.
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It would be prudent, therefore, if the ethical and data protection issues could be
formally clariﬁed, and a clear political and legal statement should be made about
the circumstances under which samples may or may not be taken without violating
the rights of individuals against the risk of illegal surveillance. The European
directive on the protection of individuals with regard to the processing of personal
data (European Parliament, 1995) is of relevance in this context. Such issues should
be taken into consideration in the conduct of ﬁeld trials.
Greater clarity is needed regarding current and required legislation concerning
sampling procedures. It is recommended that all involved stakeholders should
contribute to a full and open discussion of the ethical and legal issues that are
involved in the application of wastewater analysis.
Concluding comments
The application of wastewater analysis to the investigation of illicit drug use
represents an innovative approach to the monitoring of this problem. This method is
most useful for drug surveillance at the community level. It could be used as a drug
surveillance tool to assist public health and law enforcement ofﬁcials in identifying
patterns of drug use across municipalities of all sizes. And because wastewater
sampling and analysis can be conducted on a daily, weekly or monthly basis,
the data can be used to give a real-time measure that provides communities with
more opportunity for monitoring the impact and effectiveness of prevention and
intervention activities.
As with any new approach, wastewater analysis may be expected to generate a
polarised response. Both the advantages and the disadvantages can be overstated.
There remain many issues for which existing empirical data are either missing or
very limited. Also, it can undoubtedly be expected that concerns will be expressed
about the possible risks associated with this method. The currently available
technologies for wastewater analysis increasingly provide opportunities for the
investigation and interpretation of matters which touch upon issues of political or
social sensitivity. In this case, there are potentially sensitive issues relating to intrusion
and potential loss of privacy, and these matters may form the basis for potentially
controversial discussions. It is to be hoped that a clear-headed assessment will be
made of the advantages and implications of the developing science.
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Chapter 2: Estimating community drug use
Ettore Zuccato, Chiara Chiabrando, Sara Castiglioni,
Renzo Bagnati and Roberto Fanelli
Introduction
The aim of this chapter is to provide an overview of the procedure we have
developed to estimate drugs consumption in communities by analysing wastewater
from treatment plants. The method involves measuring the levels of breakdown
products of illicit substances excreted in the urine of consumers. The levels of
breakdown products measured in wastewater are then scaled up to calculate
consumption of the parent drugs among the population. Although this ‘sewage
epidemiology’ approach provides objective consumption data in real time, some
potential sources of uncertainty need to be addressed. Although measurements of
levels in wastewater utilise speciﬁc and reproducible analytical methods, such as
mass spectrometry, back-calculation is based on assumptions that might introduce
some bias. This chapter therefore intends to give an overview of the procedure
and to discuss potential drawbacks and margins of improvement of this method.
Sewage epidemiology
The ‘sewage epidemiology’ approach attempts to estimate epidemiological data
regarding substance consumption from measurements of urinary breakdown
products in pooled wastewater, e.g. in an urban sewage treatment plant. For
example, measurements of the residues and by-products of drugs may be used
to estimate the total consumption of these substances in a population (Dove, 2006).
The prevalence of drug use is currently estimated by subjective methods,
such as population surveys (EMCDDA, 2005), which rely on self-reporting of
socially undesirable behaviour and are thus likely to underestimate the true ﬁgure
(EMCDDA, 1997). Here, we describe and discuss an alternative approach to
estimate, objectively, consumption of illicit drugs in large communities. This approach
is particularly suitable for monitoring consumption in real time, enabling prompt
identiﬁcation of changing trends, which is pivotal to the identiﬁcation of problems,
the planning of selective countermeasures and the assessment of the effectiveness
of treatments.
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Combining ﬁndings from these methods with those from classical population surveys
would provide an integrated and potent tool to study drug use trends in the general
population and would enable the phenomenon to be continuously reviewed.
The possibility of using ‘non-intrusive drug monitoring at sewage treatment
facilities to determine collective drug usage parameters at community level’ was
ﬁrst proposed by Daughton (2001). Subsequently, we implemented this idea
by measuring the level of benzoylecgonine (BEG), a metabolite of cocaine, in the
sewage water of some Italian cities, and from these measurements we estimated
the levels of consumption of this drug in those localities (Zuccato et al., 2005).
We have now extended this procedure to other illicit drugs, such as opioids,
amphetamine-type stimulants and cannabis, which we have identiﬁed in the
wastewater of treatment plants (Castiglioni et al., 2006).
This chapter aims to provide an overview of the ‘sewage epidemiology’ approach
and to discuss potential sources of variability and possibilities for improvement.
Sample collection and analysis
Several studies have reported that therapeutic and veterinary drugs excreted by
humans and animals end up in the aquatic environment via the sewage system
(Ternes, 1998; Zuccato et al., 2000; Kummerer, 2001; Heberer, 2002; Kolpin et
al., 2002). We found published evidence that environmental levels of widely used
therapeutic drugs approximately reﬂect the total amounts consumed by the local
population, as calculated from prescription ﬁgures (Calamari et al., 2003; Castiglioni
et al., 2004; Heberer and Feldmann, 2005). It appears that local wastewater and
the receiving surface waters can be viewed as a sort of transient ‘depository’ for any
sufﬁciently stable compound excreted by the local population.
Thus, provided factors such as pharmacokinetics and metabolism and the
environmental fate of excretion products are appropriately taken into account, the
environmental load (i.e. the amounts entering the environment over time) of a drug
or its major metabolites or both, whether therapeutic or illicit, can be used as an
indicator of consumption of that drug by the local population.
Although it is theoretically possible to sample both wastewater and surface waters, it
is clear that only sampling of untreated water (inﬂuents) at the wastewater treatment
plant (WWTP) level can be recommended for population studies because the
concentration of the target substance in the receiving surface waters is determined
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by the amounts persisting in the efﬂuent of the WWTP following degradation or
removal of the substance, at a rate that is variable and sometimes unpredictable.
Moreover, in the case of a river, the degree of dilution and the size of the
contributing population can be difﬁcult to be estimated accurately, and sampling
is also affected by several variables. The representativeness of the samples may
therefore be inadequate, and analysis might provide unreliable results. In contrast, in
a WWTP, the inﬂuent (untreated water) can be adequately sampled by an automatic
sampling device, and ﬂow rates and the size of the contributing population can be
reliably determined.
In theory, estimates of drug consumption obtained in this way should fall within the
range of the ofﬁcial ﬁgures. In practice, the method of collecting samples and the
assumptions made in the calculations mean that the true consumption is only likely
to be underestimated. For example, of the drug excretion products entering a
sewage system, an unknown fraction may be lost or degraded before reaching the
sampling site. In addition, the only source of drug metabolites present in wastewater
is likely to be human excretion and, as these substances cannot accumulate in
ﬂowing waters, this method can again only underestimate the true value.
The starting point of our procedure is the selection of the molecules for analysis.
We chose a range of illicit drugs that are among the most used worldwide, i.e.
cocaine, opioids, cannabis and amphetamine-type stimulants. We then selected
relevant excretion products of these drugs as analytical targets for wastewater
monitoring (drug target residues, DTRs), after having considered the available
knowledge on the metabolic fate of each active drug. The chosen DTRs were the
main urinary metabolites in the case of cocaine, heroin and cannabis, and the
unchanged parent drug in the case of amphetamine-type stimulants (Ambre, 1985;
Smith et al., 2001; Baselt, 2004; Maurer et al., 2006), as detailed below.
Cocaine: Both cocaine and BEG were measured. In humans, cocaine is mainly
excreted in the urine as BEG and only a small percentage is excreted as the
unchanged drug. BEG levels were used to back-calculate cocaine consumption,
as the only plausible source of BEG in wastewater is the urine of cocaine consumers.
However, evaluating the presence of both cocaine and BEG can be useful to
distinguish consumption from disposal by trafﬁckers or users.
Opioids: Morphine was selected as a DTR. As several sources may account for the
presence of morphine in wastewater, such as illicit use of heroin and therapeutic use
of morphine and codeine, we also measured 6-acetylmorphine, a speciﬁc metabolite
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of heroin. Morphine is excreted mainly as a glucuronide conjugate. However, we
measured free morphine only, as glucuronides are hydrolysed to morphine by the
beta-glucuronidases of faecal bacteria present in untreated wastewater (D’Ascenzo
et al., 2003) and during wastewater treatment (Ternes et al., 1999).
This was conﬁrmed by stability studies (Table 1) and by the detection of
morphine-3 -D-glucuronide in random samples.
Amphetamine-type stimulants: We chose to monitor the parent compounds of
amphetamine, methamphetamine and MDMA (ecstasy), as they are reported to be
excreted mainly unchanged.
Cannabis derivatives: We measured 11-nor-9-carboxy-Δ9-tetrahydrocannabinol
(THC-COOH), the major urinary metabolite of Δ9-tetrahydrocannabinol (THC),
the primary active constituent of cannabis. THC-COOH can be excreted as the
glucuronide conjugate, but we monitored only the free compound for the reasons
explained above for morphine.
Table 1: Stability of drug target residues in wastewater
Drug target residue Amount spiked
(ng/l)
Difference after 3 days
(%) ± SD (%)
Benzoylecgonine 5 000 +13.9 ± 0.37
Cocaine 2 000 –36.1 ± 2.19
Morphine 2 000 +25.6 ± 1.45
6-Acetylmorphine 500 –4.0 ± 0.53
Morphine-3 -D-glucuronide 500 –96.3 ± 6.28
Amphetamine 500 +4.9 ± 0.04
Methamphetamine 500 +0.3 ± 0.01
MDA 500 –4.4 ± 0.15
MDMA 500 +0.8 ± 0.02
MDEA 500 –2.5 ± 0.05
11-Nor-9-carboxy-Δ9-THC 2 000 –7.8 ± 0.17
Note: The results are expressed as percentage differences between initial and ﬁnal concentrations of
each substance after three days’ storage at 4°C (Castiglioni et al., 2006). SD = standard deviation.
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A fraction of the drugs could theoretically be degraded before reaching the
sampling site, and this would result in consumption levels being underestimated.
Controlling for this factor involves experimental determination of the chemical and
biological stability of the drug’s excretion products. This was achieved by spiking a
sample of wastewater with a known concentration of the target molecules
and measuring the concentration after three days’ storage at 4 °C (Table 1).
Corrections for degradation can then be introduced in calculations.
The second step is to establish a suitable method for analysis of the selected
DTRs. Samples of urban wastewater were enriched with internal standards
labelled with a stable isotope and subjected to solid-phase extraction. Analysis
requires highly selective and thoroughly validated methods, such as liquid
chromatography–tandem mass spectrometry (Castiglioni et al., 2006). In our
opinion, the inaccuracy in estimating consumption that may derive from the
analytical variability is of little importance as this potential source of error can be
adequately controlled by using analogues of the DTRs labelled with suitable stable
isotopes as internal standards.
Back-calculation and assumptions
The concentrations of DTRs in wastewater conveyed to the treatment plant, reﬂecting
the amounts collectively excreted in urine, can be used to estimate consumption
of the parent drugs. For instance, as about half of a dose of cocaine is excreted in
the urine as BEG, and only a small fraction as the unchanged drug (Zuccato et al.,
2005), we used the concentrations of BEG in wastewater to estimate the amounts of
cocaine consumed in a locality. However, we also measured cocaine concentrations
to verify that the BEG/cocaine ratio was stable and in the expected range, which
would conﬁrm that the source of these substances was human consumption. If a
sampling site were to be contaminated by the accidental or intentional disposal of
a signiﬁcant amount of cocaine, then the normal BEG/cocaine ratio would be altered
in favour of cocaine. BEG loads (g/day) at each sampling site — calculated from
the BEG concentration in water (ng/l) and water ﬂow rate (m3/day) — were
multiplied by a factor of 2.33 to estimate the load of parent cocaine. This factor
was derived from the BEG/cocaine molar mass ratio (0.954) and the average molar
fraction (45%) of a cocaine dose that is excreted as BEG according to different
studies (Ambre, 1985; Baselt, 2004). Cocaine loads were then related to the local
population equivalents (i.e. the number of people served by a WWTP). The estimated
consumption (g per day per 1000 people) at each site was referred both to the
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Chapter 2: Estimating community drug use
general population and to young adults (15–34 years), a group that reportedly
accounts for almost all consumers (Ministero del Lavoro, 2001). The data were also
expressed as the number of doses per day per 1000 people, assuming 100 mg
as an average dose (UNODC, 2004).
We have now extended this procedure to the other illicit drugs, such as opioids,
amphetamine-type stimulants and cannabis, which we have identiﬁed in the
wastewater of treatment plants (Castiglioni et al., 2006).
In the case of amphetamine, methamphetamine and ecstasy, calculation of
consumption assumed that the proportion of an oral dose excreted unchanged in
the urine was 30%, 43% and 65%, respectively (Baselt, 2004).
As the major metabolic product recovered in the urine after consumption of both
morphine and heroin is morphine, estimates of heroin consumption were calculated
after subtracting the amount of morphine attributable to consumption of therapeutic
morphine based on known morphine consumption in Italy. Our calculations assumed
that 42.5% of a dose of intravenous heroin and 85% of an oral therapeutic dose
of morphine is excreted in the urine as morphine (Baselt, 2004) and that the
heroin–morphine molar mass ratio is 1.29 (Baselt, 2004). Levels of 6-acetylmorphine,
a speciﬁc but minor metabolite of heroin, could be also used to reﬁne calculations.
However, our preliminary analysis found higher than expected concentrations of
6-acetylmorphine in wastewater, revealing a need for further studies.
Estimates of THC consumption, based on THC-COOH loads in wastewater,
took account of previous ﬁndings in volunteers that, for each milligram of THC
smoked as resin or herbal cannabis, 6 micrograms of THC-COOH is excreted
in the urine (Huestis et al., 1996) and that the THC/THC-COOH molar ratio is 0.91.
The number of doses consumed by a population can be estimated by dividing the
total consumption in milligrams by the size of a ‘typical consumption unit’:100 mg for
cocaine, 30 mg for amphetamine and methamphetamine, 100 mg for ecstasy and
30 mg for intravenous heroin (UNODC, 2004). For therapeutic oral morphine, we
used a deﬁned daily dose (DDD) of 100 mg (WHO, 2007). For cannabis, we based
our calculations on evidence that the concentration of THC in street resin or herbal
cannabis in Italy has recently increased to an average of 15%, or 125 mg per dose
(Camera dei Deputati, 2007) (Table 2).
The procedure described here has certain limitations in that the accuracy of the
calculated consumption estimates is subject to potential sources of error and
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variability related to some of the assumptions. For instance, the values used to
correct for the metabolism and percentage excretion of unchanged drug are
based on published average values generally experimentally measured in healthy
volunteers, who might not be representative of the whole population, and sample
sizes are sometimes rather small. The accuracy could be improved by using an
average drug-to-metabolite fractional conversion factor obtained from multiple
Table 2: Selection of drug target residues (DTRs)
for illicit drug monitoring in wastewater
Drug DTR Relation
of DTR
to parent drug
Drug dose
excreted
as DTR (%)
Molar
mass
ratio
Correction
factor
Cocaine Benzoylecgonine Major
metabolite
45 1.05 2.33
Cocaine Parent drug
(minor excretion
product)
Heroin Morphine Major but
non-exclusive
metabolite
42 1.29 3.08
6-Acetylmorphine Minor but
exclusive
metabolite
Amphetamine Amphetamine Major excretion
product
30 1.0 3.3
Methamphetamine Methamphetamine Major excretion
product
43 1.0 2.3
Ecstasy Ecstasy (MDMA) Major excretion
product
65 1.0 1.5
Cannabis THC-COOH Major
metabolite
of THC
0.6 0.91 152
Note: The correction factor takes into account the percentage of parent drug excreted as the chosen
DTR and the parent drug-to-DTR molar mass ratio. Morphine can derive from illicit heroin use, but also
from consumption of therapeutic morphine and codeine (see text).
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thorough studies. In addition, studies providing new, updated and accurate data on
the metabolism of drugs in consumers would increase the precision of the estimates.
Another potential source of uncertainty is based on the difﬁculty of characterising
the population served by a given WWTP at any particular time. Although the size
of the population can be estimated, for instance by measuring organic carbon in
wastewater, or simply by considering the wastewater ﬂow rates during days with no
rain, it is difﬁcult to identify changes in the resident populations, e.g. at weekends.
So, for example, it is not possible to determine whether an apparent increase in
cocaine consumption on Saturdays (Figure 1) is due to an increase in consumption
by residents or to an increase in the number of consumers resulting from an increase
in the resident population at the weekend. Resolving this issue would require
parallel surveys of the target population.
Reproducibility of the results
As discussed above, this method of determining collective consumption has some
intrinsic limitations. Nevertheless, we believed that it was worth testing whether or
not this analytical method offers any improvement over existing indirect methods
or provides any valuable additional information.
The results of a repeated survey of the Nosedo WWTP in Milan (sampling was
carried out daily during three non-consecutive weeks) gave us some useful
information for discussion. The variation in average daily excretion rates for
benzoylecgonine, THC-COOH and morphine were generally low, both between
different days and between different weeks (relative standard deviation < 16% over
seven days and < 19% over three weeks). When replicate data grouped according
to the day of the week were analysed, we found that BEG concentration (indicating
cocaine consumption) peaked on Saturdays and was signiﬁcantly higher than on
Mondays (P < 0.01), Tuesdays and Wednesdays (P < 0.02 vs. one-way analysis
of variance and Dunnet’s test) (Figure 1). Cocaine and amphetamine-type stimulants
also exhibited an increasing but non-signiﬁcant trend over the weekend, whereas
morphine and THC-COOH consumption remained constant throughout the week,
suggesting a rather steady use of heroin and cannabis in Milan.
Overall, there is evidence from the weekly surveys in Milan that the average daily
excretion rates for major DTRs appear to be reproducible both on different week
days and between different weeks.
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
N
o
v
0
7
,
2
0
0
8
1
0
:
4
5
:
1
4
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
Assessing illicit drugs in wastewater
30
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
0
2
4
6
8
10
12
14
16
Thu Fri Sat Sun Mon Tue Wed
Kg
pe
r
da
y
D
os
es
pe
r
da
y
pe
r
1
00
0
in
ha
bi
ta
nt
s
Cocaine doses Quantity of cocaine
Figure 1: Day-by-day monitoring of cocaine equivalents in sewage water entering
Milan’s wastewater treatment plant, which serves 1.25 million people. Cocaine equivalents
were estimated from benzoylecgonine levels (see text) (Fanelli et al., 2006).
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Figure 2: Proﬁle of illicit drug use in Milan based on analysis of wastewater entering
the Nosedo treatment plant (serving 1.25 million inhabitants). Comparison of the results
obtained in 2006 and 2007. Doses per day were back-calculated from excretion rates
of drug target residues after correction, as detailed in the text. Estimates of heroin
consumption were back-calculated after subtracting the fraction of morphine probably
excreted as a by-product of therapeutic morphine, as determined from known morphine
consumption in Italy. The ‘amphetamine-type stimulants’ bar represents the total number of
doses of MDMA (ecstasy), methamphetamine and amphetamine.
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Chapter 2: Estimating community drug use
As previously discussed, estimating drug consumption by this method could be
a useful tool to proﬁle and monitor the drug use habits of the consumers and to
promptly identify changes in trends. A comparison of the results obtained in 2006
with those of a survey carried out in March 2007 (ﬁve days’ sampling at the Milan
WWTP) gives an example of this potential (Figure 2). Our preliminary results
indicate that consumption of cannabis and heroin in Milan decreased between
2006 and 2007 (by 26% and 32%, respectively) and that consumption of cocaine
remained relatively stable, whereas consumption of amphetamine-type stimulants
(ecstasy, methamphetamine and amphetamine) increased substantially (+127%).
Overall, these results would suggest that the behaviour of consumers changed
between the two sampling dates: an increase in the consumption of amphetamine-
type stimulants was offset by reduced consumption of cannabis, and the known
decreasing trend in heroin was conﬁrmed. However, before drawing any conclusion,
we must take into account the fact that these data were obtained over a short time
span only, and should be conﬁrmed by long-term monitoring data.
Conclusion and perspectives
Surveys of the general population are useful for determining patterns of drug use,
but they are expensive to carry out and are too slow to detect changing trends
promptly (EMCDDA, 1997). Here, we propose and describe a new objective
approach to estimate consumption of illicit drugs.
Clearly, this method still requires validation. This could be done indirectly, i.e. by
comparing consumption estimates obtained in ﬁeld trials with local prescription
ﬁgures for a pharmaceutical drug, for instance methadone or other drugs with
chronic indications, such as atenolol or carbamazepine; in fact, this has been
already done, at least partially (Heberer and Feldman, 2005; Lindberg et al., 2005).
However, we believe that a proper validation will require direct comparison of ﬁeld
trial results with ﬁndings regarding drug use from parallel local population surveys.
Once properly validated, patterns and trends of drug use in large communities could
be monitored by this method, which will provide a useful complement to current
ofﬁcial tools. This approach would seem to be particularly suitable for proﬁling
consumption in real time, for which other methods are lacking, and for the prompt
identiﬁcation of changes in trends and habits, which is essential for planning and
prioritising countermeasures. Combining ﬁndings from this method with those from
population surveys would offer an integrated tool to monitor drug use.
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Teresa Summavielle
Introduction
As a precondition for quantifying drug consumption based on the measurement
of drug breakdown products in wastewater samples, it is necessary to determine
the metabolic pathways of speciﬁc substances and the extent to which they are
degraded in the body before reaching the wastewater system. One of the outcomes
of the ﬁrst multidisciplinary meeting on this subject, held in Lisbon in April 2007,
was the conclusion that cocaine and methadone should be used as test substances.
Cocaine was chosen because its distribution in Europe has been reported to be
increasing and thus there is a need for careful monitoring. Methadone was chosen
because it is a prescribed licit drug, used in heroin substitution programmes, and as
a powerful painkiller in cancer patients, as well as in veterinary anaesthesia. Cross-
matching methadone concentrations in wastewater with dispensing ﬁgures from
pharmacies may provide a better understanding of mass ﬂow in wastewater systems
in the context of potential ﬁeld trials. The wide range of sources of methadone
means that back-calculation must be carried out with particular care.
Cocaine
Cocaine is metabolised in the human body either by spontaneous hydrolysis or
by the action of hepatic esterases and plasma cholinesterase (Figure 1). The major
metabolites are usually benzoylecgonine (BEG) and ecgonine methyl ester (EME).
In the presence of ethanol, cocaine is preferentially converted into cocaethylene (CE)
by a transesteriﬁcation reaction in the liver, with CE being further transformed into
norcocaethylene (NorCE) and ecgonine ethyl ester (EEE). The presence of ethanol
also increases cocaine demethylation to norcocaine (NC), the most toxic of cocaine
metabolites. Heating of cocaine, as occurs when crack cocaine is smoked, results
in the production of anhydroecgonine methyl ester (AEME), which is hydrolysed
to anhydroecgonine (AE).
Signiﬁcant toxicity arising from the use of cocaine was not considered a problem
until puriﬁed cocaine became available for recreational use in the 1970s.
Investigations into the metabolism of cocaine also began in the early 1970s. Human
metabolism of cocaine seems to be largely dependent on the previous levels of
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exposure to this drug. Initially, most ﬁndings were limited by serious methodological
problems, such as the absence of a control group, unreliable identiﬁcation of cocaine
users and non-users, and inadequate control of confounding variables (Lester et al.,
1995). Consequently, published results are often contradictory and the mechanisms
of action of cocaine are still not fully understood. The use of consistent criteria and of
research animal models in which major confounding factors, such as polydrug use,
environment and lifestyle (Neuspiel, 1995) are well controlled is clearly necessary
(Dow-Edwards, 1991; Vorhees, 1995; Spear et al., 1998; Frank et al., 2001; Henck,
2002). Here, we address the metabolism of cocaine, aiming to show which are the
main human metabolites and how individual variability and environment and social
Figure 1: Metabolism of cocaine.
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behaviour can inﬂuence the course of cocaine biotransformation. The metabolism
of methadone is also described in a simplistic way. Although the methadone found
in the sewage system may come from different sources, there are reliable sources
of data sources on its availability, prescription and use. Therefore, potentially,
methadone could provide a good control for back-calculation in sewage systems.
Blood concentrations
Different routes of administration will result in different blood levels of cocaine,
and these will peak at different intervals after administration. Although plasma
concentrations are generally proportional to the dose of cocaine ingested, the exact
relationship will depend on the route of administration. This is because the potent
vasoconstrictive properties of cocaine (Knuepfer et al., 1994) mean that cocaine
inhibits its own absorption, increasing the time for maximum blood concentration to
be achieved compared with intravenous administration. Thus, in the case of cocaine
consumed by snorting, leaf chewing or even smoking, the higher the dose, the
slower the absorption.
On average, chewing 12–15 g of leaves (with an alkaloid content of usually less
than 0.5%) results in ingestion of around 75 mg of cocaine. In a novice chewer, who
may spit out saliva, blood concentration will peak at around 38 ng/ml after 1 hour;
however, in experienced users, who swallow saliva, peak blood concentration
averages 249 ng/ml (individual variation can range from 130 to 859 ng/ml)
(Holmstedt et al., 1979; Paly et al., 1982).
Previous studies have shown that intranasal application of cocaine, which mimics
the effect of snorting, in doses of 1.5 mg/kg, i.e. 90 mg in an average 60-kg man,
(equivalent to two to three ‘lines’ of cocaine), results, on average, in blood peaks
of 120 ng/ml at 15 minutes and 470 ng/ml at 30 minutes (Brogan et al., 1992).
Cocaine persists on the nasal mucosa for at least three hours after exposure,
probably because of its vasoconstrictive properties (Van Dyke et al., 1976). These
levels are similar to those observed in an experienced cocaine chewer for a similar
dose of the drug.
Intravenous cocaine use, on the other hand, will result in much higher levels of the
drug in the blood. Injection of 100 mg will result in a peak blood concentration of
700–1000 ng/ml in ﬁve minutes, which implies the need for multiple injections to
maintain persistent high levels of the drug (Barnett et al., 1981).
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Benzoylecgonine
At pH values above 4, cocaine is rapidly hydrolysed to benzoylecgonine (BEG),
its main metabolite. BEG has a urinary excretion half-life of 6–8 hours (Ambre,
1985) and, in general, can still be detected in the urine 48 hours after cocaine
administration (Saxon et al., 1988). Although BEG was originally believed to be
pharmacologically inactive, it was later shown to be able to cause vasospasm.
As BEG has no adrenergic properties, it probably acts by altering calcium inﬂux
and calcium channel regulation (Madden et al., 1995). Although results obtained
in animal models support a possible role for BEG in the genesis of stroke and
myocardial infarction, which sometimes occur hours after cocaine ingestion,
there are no clinical data to support this hypothesis.
No studies have shown any psychoactive properties of BEG. Nevertheless,
in vitro studies have demonstrated that BEG is inherently cytotoxic (Lin and
Leskawa, 1994). Although most BEG is formed from spontaneous hydrolysis,
human carboxylesterase 1 (hCE-1), a microsomal serine hydrolase found in the
liver, intestine, kidneys, lungs, heart and plasma, is capable of catalysing the
conversion of cocaine to BEG (Bencharit et al., 2003).
Ecgonine methyl ester
The other major metabolite of cocaine is ecgonine methyl ester (EME) (Stewart et
al., 1979; Matsubara et al., 1984; Cone et al., 1998; Kolbrich et al., 2006). Cocaine
is metabolised to EME by pseudocholinesterase and hCE-2. EME is very stable at
pH values between 3 and 5, but as pH increases, EME is hydrolysed to ecgonine.
Above pH 9, EME is no longer detectable (Vasiliades, 1993). Thus, circulating EME is
rapidly converted into ecgonine.
After death, as a result of anaerobic metabolism, acidity increases and spontaneous
hydrolysis ceases, although enzymatic synthesis of EME persists and it accumulates,
altering the BEG/EME ratio (Karch, 1996).
The rate of metabolism of cocaine to BEG or EME varies between individuals,
a ﬁnding that has been attributed to phenotypic variations in pseudocholinesterase,
which binds to cocaine with different efﬁciencies (Xie et al., 1999). EME is
considered to be the least toxic of all cocaine metabolites. Although some authors
have suggested that it may afford some protection from cocaine toxicity (Hoffman
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et al., 2004), recent reports suggest that EME is involved in vasodilation processes
(Madden and Powers, 1990; Pane et al., 1997; Hollander and Henry, 2006).
Cocaethylene
In the presence of ethanol, cocaine undergoes transesteriﬁcation to cocaethylene,
a reaction that is catalysed by hCE-1 in the liver or by ethyl ester synthetase
(widely distributed in the body) (Hearn et al., 1991; de la Torre et al., 1995; Farre
et al., 1997; Harris et al., 2003). Several studies have found that cocaethylene is
more toxic than cocaine and that it readily crosses the blood–brain barrier and has
similar afﬁnity for the dopamine transporter protein (DAT) (McCance et al., 1995;
McCance-Katz et al., 1998; Pennings et al., 2002; Goldstein et al., 2004).
Alcohol intensiﬁes the psychotropic effects of cocaine and increases the incidence
of violent behaviour (Pennings et al., 2002). Cocaethylene has a longer elimination
half-life than cocaine (Laizure et al., 2003), and can be further metabolised to BEG,
norcaethylene and EME (Cone et al., 1994). The presence of alcohol has also been
shown to increase peak levels of cocaine, which is probably associated with alcohol-
induced pH shifts that reduce spontaneous hydrolysis to BEG (Farre et al., 1997).
Norcocaine
Hepatic necrosis due to cocaine metabolism results from the conversion of cocaine
to norcocaine, the most toxic metabolite of cocaine. It has been shown that
P450 enzymes participate in this process; cocaine being ﬁrst demethylated to
norcocaine and then metabolised to N-hydroxynorcocaine by brain FAD-containing
mono-oxygenases (Kloss et al., 1984a,b). Further enzymatic breakdown in brain
microsomes results in norcocaine hydroxide, which, although itself stable, can
be oxidised to the norcococaine nitrosodium ion, a highly reactive compound
that reduces glutathione levels and increases lipid peroxidation and protein
carbonylation (Evans, 1983; Shuster et al., 1983; Kloss et al., 1984b).
Additionally, norcocaine can be hydrolysed to benzoylnorecgonine.
Anhydroecgonine methyl ester
Anhydroecgonine methyl ester (AEME) is a pyrolysis product of cocaine that is
excreted solely in the urine of crack smokers. AEME is converted to ecgonidine,
probably through enzymatic hydrolysis (Scheidweiler et al., 2000, 2003). AEME
chemically resembles other compounds that have cholinergic properties and may
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therefore be responsible for the decrease in air ﬂow observed in crack smokers
(Chen et al., 1995; Kleerup et al., 2002).
Excretion
Cocaine is eliminated almost entirely by renal clearance (Chow et al., 1985).
Disposition of cocaine has been characterised by one- and two-compartment open
kinetic models (e.g. Ambre, 1985; Cone, 1995) and by non-compartmental models
(Kolbrich et al., 2006). Despite the justiﬁcations presented in most papers, none
of the current models fully explains the disposition of cocaine. A detailed study
investigating the large number of variables that can signiﬁcantly affect the rate of
cocaine metabolism and the formation of its various metabolites is needed.
Conclusion
The assumption that 30–50% of ingested cocaine is usually converted to BEG
is clearly insufﬁcient. The use of BEG quantiﬁcation to estimate levels of cocaine
consumption should, therefore, take account of the fact that the metabolism of a
ﬁxed dose of cocaine ingested by the same route will vary between individuals
depending on sex (Dhossche, 2000; Visalli et al., 2005), age (Sandberg et al.,
1995), body mass (brown fat tissue avidly retains cocaine) (Som et al., 1994), kidney
and liver function, interaction with other drugs (such as alcohol), previous drug use
history and genetic variability, including variation in receptors, transporters and
enzyme polymorphism (Evans, 2003; Maurer et al., 2006).
Methadone
The main metabolites of methadone are 2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EDMP)
(Figure 2). Methadone undergoes pharmacological inactivation by mono- and
di-N-demethylation, followed by spontaneous cyclisation to EDDP catalysed by
cytochrome P450 3A4 (CYP3A4). Methadone may also be metabolised to a much
smaller extent to methadol and normethadol; however, these metabolites can also
originate from the deacetylation of acetyl methadone (LAAM).
Methadone is a diphenylpropylamine derivative (6-dimethylamino-4,4-diphenyl-3-
heptanone) that contains the same basic structures as other opioids. Its high oral
bioavailability and a long elimination time make it suitable for the treatment
of heroin addiction and for analgesia in cancer patients. Methadone is available
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Figure 2: Metabolism of methadone.
on the market as a racemic mixture of two enantiomers. (R)-methadone has a 10-fold
higher afﬁnity for opioid receptors, and therefore is much more pharmacologically
active (Olsen et al., 1977; Kristensen et al., 1995; Eap et al., 2000). Methadone
taken orally is detectable in the plasma about 30 minutes after administration
(Inturrisi and Verebely, 1972). All oral formulations of methadone — solid tablets,
dispersible tablets and liquid concentrate — are intrinsically equal in terms of
their absorption and metabolism (Gourevitch et al., 1999).
Plasma concentrations
Previous kinetic studies have found a strong relation between a given dose
of methadone and the resultant plasma levels. For example, Wolff et al. (1991a)
reported a linear correlation between oral dose of methadone and plasma
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concentration over the range 3–100 mg per kilogram body weight, with each mg/kg
dose increase resulting in an increase in plasma methadone concentration of
263 ng/ml. Despite this, inter-individual variability in absorption and metabolism
is now believed to be the main factor responsible for the unpredictability of plasma
levels and clinical effect at different doses.
According to recent data, the plasma concentration of methadone follows a
bi-exponential curve, with a rapid -phase, corresponding to the transfer of
methadone from the central compartment to the tissue, and a slow -phase that
represents the elimination stage (Verebely et al., 1975; Nilsson et al., 1982a;
Wolff et al., 1991a,b; Rostami-Hodjegan et al., 1999; Ferrari et al., 2004). The
maximum plasma concentration is reached between one and six hours (average
2.5–4.4 hours). The greatest inter-individual variation appears to occur during
the elimination phase. Transfer to tissues such as liver, kidneys, lungs and brain
occurs rapidly because methadone is very lipophilic (Dole and Kreek, 1973). The
methadone that remains in the blood (1–2%) is in equilibrium with methadone bound
to plasma globulins and can be altered by factors such as stress and addiction
(Olsen, 1972). According to some authors, plasma levels and excretion rates may
vary during prolonged exposure (Verebely et al., 1975; Holmstrand et al., 1978).
After administration, methadone is converted via N-demethylation into several
metabolites that are apparently inactive. The elimination of methadone occurs
through urine and faeces (20–50% unchanged) (Nilsson et al., 1982b). The
proportion of methadone excreted unchanged depends on the pH of the urine,
increasing with increasing acidity; at pH values lower than 6, levels of unmodiﬁed
methadone can be 3–8 times higher compared to those at higher pH values (Baselt
and Casarett, 1972a,b; Nilsson et al., 1982b). The most important enzymes in
methadone metabolism are cytochrome P450 proteins known as CYP enzymes
(Leavitt et al., 2000; Shinderman et al., 2003; Crettol et al., 2005). These enzymes
are found mainly in the liver but can also be found in other organs. CYP3A4 and
CYP2B6 are the major CYP isoforms involved in methadone metabolism, with
CYP2D6 contributing to a minor extent (Crettol et al., 2006). CYP polymorphisms
also add to the inter-individual variability of methadone kinetics.
Another metabolically important protein is P-glycoprotein, which is found mainly
in the intestine and along the blood–brain barrier (Wang et al., 2004; Nanovskaya
et al., 2005; Ortega et al., 2007), and which functions as a pump, transporting
methadone out of cells lining the intestinal wall and back into the lumen. Therefore,
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some of the methadone ingested and absorbed by the intestine is pumped back
and never reaches the blood circulation. Thus, differences in the expression of
P-glycoprotein also account for inter-individual variation in methadone metabolism
(Leavitt et al., 2000).
Excretion
Methadone is primarily eliminated from the body by metabolism in the liver.
Among the nine metabolites of methadone that have been identiﬁed in human
urine, the main breakdown products of methadone are 2-ethylidene-1,5-dimethyl-
3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline
(EDMP). Methadone undergoes pharmacological inactivation by mono- and di-N-
demethylation, followed by spontaneous cyclisation to the EDDP catalysed by
intestinal, hepatic and expressed cytochrome P450 3A4 (CYP3A4) (Eap et al., 2001;
Shinderman et al., 2003; Ferrari et al., 2004; Crettol et al., 2005). It has been
shown that the process of N-demethylation is not markedly stereoselective, although
CYP2D6 may be involved in other oxidative pathways involving the (R)-methadone
form. EDDP accounts for 3–25% of the dose excreted in the urine over the ﬁrst 24
hours. However, excretion of EDDP is relatively slow and it may still be present in
the urine 2 days after the last ingestion of methadone. Urinary excretion of EDPM
accounts for less than 1% of the ingested dose. Methadone, EDDP and EDMP
also undergo hydroxylation in the para-position of one of the phenyl rings and
glucuronide conjugation.
Methadone is also metabolised to two minor pharmacologically active metabolites:
methadol and normethadol. However, these metabolites can also be originated
by the deacetylation of acetyl methadone (LAAM) (Kaiko et al., 1975; Kreek, 2000).
Other drugs that compete for the same binding sites in the plasma, or which are
metabolised by the same enzymes in the liver, can modify the action of methadone,
increasing or decreasing the amount of unaltered methadone that is excreted
and the rate of excretion (for review, see Stout and Farrell, 2003). Nevertheless,
if both methadone and EDDP are monitored in the urine, it is still possible to estimate
the ingested dose.
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Chapter 4: On the occurrence and fate
of illicit substances in sewer systems
Jörg Rieckermann
Introduction
This chapter provides an overview of current knowledge regarding the transport
and fate of illicit drugs in drainage systems. The representativeness of measured
data can be evaluated completely only when the load pattern of a substance at
the monitoring point is known, which in turn requires a detailed understanding
of wastewater systems. The chapter is structured as follows. First, the patterns of
discharge of drugs to sewers, e.g. in urine, are addressed brieﬂy. Then, in-sewer
processes are described and their relevance for accurate back-calculations of usage
ﬁgures is discussed. Finally, issues regarding the monitoring of drug loads over time
are presented. From an environmental engineering perspective, the evaluation and
prediction of drug loads in wastewater systems is a complex and challenging topic
that requires a level of knowledge of the processes involved (either as models or
experimental data) that is beyond the scope of this chapter. Therefore, references
are given where possible. Again, cocaine serves as a model substance, as it is the
illicit substance for which the greatest amount of information is available.
Assessing cocaine loads in sewers
Urination patterns
As described in Chapter 3, cocaine and its metabolites are excreted mainly in
urine. The spatiotemporal pattern of urination (also called voiding or micturition
in medical literature) in a catchment depends on where, when and how much
is voided. While voiding patterns are clearly stochastic, they are not uniformly
distributed over time or the catchment area, with certain factors, e.g. work
schedules, tending to result in peaks and troughs. Voiding patterns have been
mainly investigated in medical research (Larsson and Victor, 1988; Boedker et
al., 1998; Schick et al., 2003; Pﬁsterer et al., 2006), and it has been found that
people use the lavatory approximately 4–6 times per day (Boedker et al., 1998;
interquartile range). In addition, recent studies have found that lavatory use
generally occurs mostly during the morning hours and in the evenings, and that this
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pattern is different at weekends (Friedler et al., 1996; Hellström and Kärrman, 1996;
Rauch et al., 2003).
Taking these ﬁndings into account, and given that drug users constitute only a few
per cent of the population, one would expect the load pattern of illicit substances
and their metabolites at any particular monitoring station to ﬂuctuate wildly, even
those serving medium or large catchments. As stated above, although the dynamics
of a drug load pattern at a monitoring point is not particularly interesting per se, it
can be critical for the correct interpretation of measured data (see further below).
Therefore, it is also important to know whether: (1) cocaine in urine could come from
sources other than drug consumption; and (2) what other sources of cocaine might
be discharged to the sewer system.
Discharge of cocaine from sources other than illicit drugs
Some studies have reported that cocaine and/or its metabolites are produced
following consumption of tea made from coca leaves (Jenkins et al., 1996; Hammett-
Stablers et al., 2003; Perrone et al., 2005; Turner et al., 2005). Although coca
tea is consumed frequently in some Latin American countries, it is less common in
other regions. Usage ﬁgures are not readily available, and it is not clear whether
cocaine is destroyed during tea preparation. Cumulative benzoylecgonine excretion
is reported to be approximately 3 mg per coca tea bag consumed (Jenkins et al.,
1996). If one assumes that a typical dose of 100 mg of cocaine leads to an excretion
of approximately 30–50 mg of benzoylecgonine, the population-wide consumption
of coca tea (e.g. in Bolivia) might lead to an overestimation of illegal drug use.
A brief literature review on cocaine use in industrial processes and on possible
industrial discharges to municipal sewers did not produce evidence that these might
be signiﬁcant. The inﬂuence of residues resulting from the use of cocaine in clinical
trials or animal studies (e.g. laboratory mice) is not considered here.
Little is known about the occurrence of cocaine residues in groundwater, which often
inﬁltrate sewer systems through cracks and ﬁssures. In some studies, drinking water
analysis has revealed traces of pharmaceuticals (Hummel et al., 2006; Zuccato et
al., 2006), but the concentrations of cocaine and its metabolites were always below
the detection limit. It is speculated that this is because chlorine residues in drinking
water have the potential to oxidise these compounds. In summary, current evidence
suggests that additional sources can generally be ignored in estimates of illicit cocaine
consumption, with the potential exception of a contribution from residues of coca tea.
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Modelling urine ﬂows in sewers
As urine is the major pathway for the excretion of not only drugs, but also of
nutrients, recent investigations in environmental engineering have modelled urine
ﬂows in sewers to assess the potential impact of nutrient control strategies on
wastewater treatment plants (WWTPs). In the literature, speciﬁcally tailored stochastic
models are used to predict ammonium loads and to evaluate the impact of control
strategies (Peters et al., 2002; Rauch et al., 2003). These models vary in complexity,
but generally incorporate variables such as urine volume, population mobility and
sewage transport. Generally, transport processes are considered in a simple fashion
and transformation is usually ignored on the assumption that the substance of interest
is not altered or degraded in the drainage system (e.g. ammonium).
To evaluate the applicability of such models, current knowledge regarding sewage
transport and transformation processes is summarised below. As environmental
analysis of illicit substances is a recently emerging ﬁeld, few experimental data
regarding the fate of illicit substances in wastewater systems have been reported.
Much more work has been done on pharmaceuticals and personal care products
(PPCPs), which will be used for comparison where appropriate.
Transport and transformation processes in sewer systems
The urban drainage system
Sewers are a key part of urban drainage systems because they transport polluted
and unpolluted water from settlements. This is necessary to maintain hygiene and
to provide ﬂood protection. A drainage system usually has the following elements:
(1) house connections; (2) manholes; (3) main sewers; and (4) retention tanks. The
system (Figure 1) is normally complemented by a WWTP, which generally removes
suspended solids and nutrients through various physical, chemical and biological
processes (Gujer, 2002).
Drainage systems are designed as combined or separate systems. In ‘separate
systems’, two complementary pipe systems are installed. Sanitary sewers (also
known as foul sewers) speciﬁcally collect the domestic and industrial wastewater
that is discharged from the house connections. Storm drains, which are independent
of sanitary sewers, carry the runoff of rain and other water that washes into city
streets. In the ‘combined system’, both sewage (from homes and businesses) and
rainwater drain into the same pipe network.
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Where possible, sewers are generally constructed as gravity sewers, enabling free
surface ﬂow, which has a number of advantages (Gujer, 2002). However, most
urban drainage systems evolve over time to meet changing needs; few are designed
from scratch. Thus, most urban sewage systems are a combination of different
separate systems and may include a number of pumping stations and alternative
systems (e.g. vacuum assisted or pressurised systems) that inﬂuence the propagation
of substances and the residence time of the wastewater. Decentralised systems
(Otterpohl et al., 1997) or systems that enable urine separation for nutrient recovery
(Henze, 1997; Larsen et al., 2004) are perceived as promising alternatives to existing
designs; but as these systems have not been widely implemented, they can currently
be ignored in the assessment of illicit drug loads.
Substance losses during storm events
As urban drainage systems capable of handling the maximum load during wet
weather are very expensive, it is generally accepted that sewerage systems will
overﬂow at some tolerable frequency, e.g. once every 10 years (Verworn, 2002).
To alleviate ﬂooding problems in both the catchment and the receiving waters,
combined sewer overﬂows (CSOs) and retention tanks, in which combined rain
and wastewater is stored temporarily and later routed to the WWTP, have
Figure 1: General representation of an urban drainage system (after Gujer, 2002).
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been introduced. During heavy storms, if the capacity of the tank is exceeded,
stormwater (with sewage) spills into the receiving waters, preventing back-up
into streets and homes. From the point of view of monitoring consumption of
illicit substances, this means that an amount of substance that is very difﬁcult to
quantify may be lost during heavy rain events. Analysis of long-term CSO data in
Germany and Switzerland has shown that sewer overﬂow occurs roughly 2% of
the time (Gujer, 2002; Weiss et al., 2006). As a rule of thumb, it can be assumed
that 50% of the diluted water is discharged (Krejci et al., 2000), which means that
the long-term substance loss would amount, on average, to approximately 1%.
As losses during individual events might be much larger, it is recommended that
monitoring campaigns should be restricted to periods of dry weather to avoid
biased results.
Regarding transport and transformation, the sewer system can be subdivided into
four compartments: (1) sewer atmosphere; (2) bulk wastewater; (3) bioﬁlm (sewer
slime); and (4) sediments. The interactions between these compartments are affected
by: (1) physical properties (e.g. slope and roughness); (2) hydrodynamic conditions
(e.g. discharge dynamics); (3) environmental conditions (e.g. temperature, pressure);
and (4) physical, chemical and biological processes (Huisman, 2001; Huisman et al.,
2003; Vollertsen et al., 2005a).
The next section describes the processes that affect the discharge of illicit drugs into
the sewer system. Only transport in gravity sewers under dry weather conditions
is considered, because it is much more difﬁcult to determine transport during
rainy weather when ﬂow is highly irregular owing to the utilisation of surcharged
manholes and tanks. In addition, only solute transport is discussed and sediment
deposition and resuspension processes are ignored, as these are still not understood
completely (Ashley et al., 2005).
Sewage transport during dry weather
To estimate drug loads in sewers, it is preferable to monitor substances at a certain
distance from the source (i.e. in the so-called ‘far ﬁeld’), where the impact of the
impulse of the discharge process on substance mixing is negligible. Transport in the
far ﬁeld is dominated by advection, dispersion (stretching of the substance cloud due
to non-uniform velocity proﬁles) and transformation processes, e.g. degradation, that
may eliminate the contaminant (Fischer et al., 1979).
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Advective transport and solute mixing
The effect of advection (solute transport with the bulk water) and dispersion
(stretching effect due to the three dimensional, non-uniform velocity ﬁeld) is
illustrated in Figure 2, which shows the results of a tracer experiment. A salt tracer
was injected instantaneously (at point 0) and the tracer curve monitored at two
points further downstream (1 and 2). It can be seen that advection transports the
tracer cloud from point 1 to point 2 in about 2 800 s. In addition, the tracer curve
is being stretched and the peak concentration is reduced substantially. For most
sewers, transport is considered one-dimensional, because solute concentrations are
usually vertically and laterally well mixed in the wastewater (Huisman et al., 2000;
Rieckermann et al., 2005a).
Longitudinal mixing in sewers is usually modelled by a dispersion coefﬁcient that
depends on the velocity distribution. An analysis of a large number of sewer tracer
experiments has shown that dispersion coefﬁcients in gravity sewers are generally
small in comparison with those of rivers and do not differ much from system to
system. Furthermore, it was found that in the absence of tracer data, prediction of
dispersion from sewer geometry and ﬂow data is limited. For details on suggested
models and the magnitude of dispersion coefﬁcients, see Rieckermann et al. (2005a).
Figure 2: (Top) Longitudinal proﬁle of a sewer section. = dosing point of tracer
(slug injection), ① = ﬁrst monitoring point (outside the initial zone), ② = second measuring point
at the end of the reach. (Bottom) Tracer curves at dosing and monitoring stations.
From Rieckermann et al. (2005a).
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Transport in house connections
Wastewater ﬂow in house connections is usually intermittent and arises mostly
from periodic use of household utilities such as the lavatory, dishwashers or
showers. To the author’s knowledge, very little is known about how a dissolved
substance is propagated through household utilities and house connections, there
apparently being only one study of solute transport from the lavatory to the main
sewer reported in the literature (Ort, 2006). The ﬁndings revealed a skewed
tracer distribution with long tails (not shown). It was posited that this pattern was
caused by backwater effects and dead zones resulting from deposits in the house
connection, which seems highly plausible as house connections are normally not
included in regular sewer inspections and are often in a structurally poor state. In
addition, house connections are often incorrectly linked to the sewer system and
are sometimes regarded a major source of wastewater losses (Barrett et al., 1997;
Ballweg, 2002; Ternes and Joss, 2006). When quantifying drug residues, signiﬁcant
losses of wastewater would lead to an underestimation of drug consumption.
Currently, no established leakage estimates are available for house connections;
partly because appropriate monitoring techniques are lacking (Rutsch et al., 2006).
Sewer leakage
Wastewater leakage occurs not only via dilapidated house connections, but also
through ageing main sewers, which may not be completely watertight (Rutsch et
al., 2006). Despite many years of research, little is known about the magnitude
of water loss through sewer leakage, because it is difﬁcult to observe in situ and
experimental methods have been lacking (Rieckermann et al., 2005a; Rutsch et al.,
2006). Our current understanding of the processes is incomplete, and contradictory
results have been reported in case studies. Some authors have suggested that
leaks in sewers undergo self-sealing as a result of particle clogging and bacterial
growth, with the result that reported losses amount to less than one per mille of
the average dry weather ﬂow (DWF) (Wolf et al., 2006). However, in experimental
studies, concentrations of wastewater-borne substances found in the groundwater
have ranged from 0 to 20% of DWF or more (Heberer, 2002; Reynolds and Barrett,
2003; Webb et al., 2003; Fenz et al., 2005; Wolf et al., 2007). It can only be
speculated as to whether these substances have entered the groundwater via a large
number of unobserved small leaks, leaky house connections or a few extreme leaks
in the system. One particular problem is that inter-study comparability is difﬁcult due
to different measurement methods and procedures (Rutsch et al., 2006).
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In general, we can conclude that excellent tools are available to describe the
hydrodynamics of sewers during dry and rainy weather. Also, apart from sewer
leakage, the transport processes of solutes such as cocaine and its metabolites
in main, are reasonably well understood. However, wastewater in sewer systems
is subject to important physical, chemical and biological changes, and the
transformation of substances in sewers, which is not normally taken into account,
might be critical for the back-calculation of consumption estimation.
Transformation processes in sewers
The conversion of wastewater in sewers has traditionally received little attention,
but recent research has conﬁrmed the importance of chemical and biological sewer
processes that have complex interdependencies (Nielsen et al., 1992; Hvitved-
Jacobsen et al., 1998; Huisman, 2001; Vollertsen et al., 2005a).
The schematic transformation of organic matter in the gas phase, the wastewater
and the bioﬁlm is shown in Figure 3 (the sediment compartment is omitted for
simplicity). The sewer bioﬁlm mainly consists of rapidly growing heterotrophic
microorganisms that degrade organic matter under aerobic conditions. However,
nitrifying bacteria and others, such as methanogenic or sulphur-reducing species,
are also present. In addition, sewer bioﬁlms also contain a large amount of inorganic
material, such as sand and zeolite, as well as fats. It is known that sewer bioﬁlms
are constantly eroded during dry weather ﬂow, but most biomass is lost during storm
events, which cause increased shear forces (Huisman, 2001).
Several attempts have been made to describe the conversion processes in sewers,
and some models have been suggested to describe transformation of organic matter,
nitrogen and sulphur under aerobic, anoxic and anaerobic conditions (Huisman
et al., 2003; Vollertsen et al., 2005b). Although there seems to be evidence that
cocaine and its metabolites undergo signiﬁcant changes (see further below), no
detailed information is currently available regarding the transformation of cocaine
and its metabolites. However, to illustrate their potential impact, the processes
involved in the removal of PPCPs in WWTPs, which are much better understood,
will be described. Ternes and Joss (2006) give a detailed description of the most
important removal mechanisms for PPCPs in wastewater: (1) stripping; (2) sorption;
and (3) biotransformation.
In sewer systems, stripping of cocaine, i.e. its removal in the gas phase, can
probably be ignored. According to Ternes and Joss (2006), even in an aeration
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tank, where air input (e.g. because of re-aeration at drops) is much higher than
in sewers, a Henry coefﬁcient (KH) > 3 × 10
–3 is necessary to observe an effect,
whereas pharmaceuticals are rather hydrophilic and have low KH values, of the
order of less than 10–5.
The sorption of pharmaceuticals in sewers attenuates the load pattern and removes
substance due to bioﬁlm erosion, which can be substantial during rain events.
According to Ternes and Joss (2006), sorption in WWTP processes can be predicted
Figure 3: (Top) Interactions and processes involved in the conversion of organic matter,
expressed as chemical oxygen demand (COD), in the sewer system. The enlargement
shows the structure and composition of sewer bioﬁlm schematically. (Bottom) Scanning
electron micrograph of a sewer bioﬁlm showing ﬁlamentous bacteria and entrapped sand
and zeolite particles. From J. Huisman (2001), ‘Transport and transformation processes in
combined sewers’, Ph.D. thesis No 13989, ETH Zürich. Reproduced with permission.
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by using solid–water distribution coefﬁcients (Kd values) (Schwarzenbach et al.,
2002). Their experimental ﬁndings suggest that, in WWTPs, sorption is less than
10% when Kd < 0.3 l/g suspended solids, but currently no experimental information
is available on Kd values of cocaine. It can only be speculated that the sorption
of cocaine is rather small and will depend on the particle concentration of the
wastewater (T.A. Ternes, 2007, personal communication). Interestingly, the sorption
behaviour was found to be different in primary and activated sludge, and the
transferability of these results to sewer bioﬁlm and sediments has yet to be proved.
In a computational experiment, Ort and Gujer (2007) model the sorption of different
PPCPs to sewer solids and bioﬁlm. They found that load pattern is attenuated
in the same order as from dispersion, but only for medium and high Kd values.
Currently, no experimental data on sorption of cocaine or its metabolites in sewers
are available, and Kd has most probably to be determined experimentally in batch
experiments (Ternes et al., 2004).
As expected, no detailed information is currently available on the biotransformation
of illicit substances in sewers or WWTPs, which might also include the conversion
of metabolites back to the parent drug. Ternes and Joss (2006) assume that,
owing to the very low concentrations involved, biotransformation of PPCPs (and,
by analogy, illicit substances) does not contribute signiﬁcantly to microbial growth.
Rather, it is speculated that some PPCPs are being degraded by enzymes that are
produced for other purposes (co-metabolism). The transformation rates apparently
depend on many factors such as: (1) the biodegradability of each substance;
(2) the biodiversity of the sludge; (3) sludge production; (4) wastewater temperature
(i.e. transformation rates correlate positively with temperature); and (5) wastewater
composition (availability of co-substrate and proportion of inert matter).
Although current knowledge regarding the transformation of cocaine and its
metabolites is very poor, there is some preliminary evidence that this aspect cannot
be ignored. Heltsley et al. (2007) compared the molar fraction proﬁle of cocaine and
its major metabolites in a wastewater sample with proﬁles reported for urine, and
concluded that cocaine undergoes signiﬁcant transformation processes within the
sewer system. Castiglioni et al. (2006) spiked batches of wastewater with different
drugs and compared the initial concentration with the ﬁnal concentrations after three
days’ storage. Although they found that the concentrations of cocaine, norcocaine
and cocaethylene decreased during storage (by 36%, 15% and 13% respectively),
an increase in the metabolites benzoylecgonine and norbenzoylecgonine (14% and
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13%) was observed. Currently, experimental data allowing even an approximate
computation of the transformation of illicit substances in sewers are lacking. For a
quantitative assessment, e.g. in predictive models, more detailed experiments are
clearly needed to establish rate constants for the individual processes.
This section has described how transport processes attenuate and stretch solute
concentrations and how transformation processes might reduce or alter cocaine
loads, which is critical for both back-calculation and monitoring of use trends.
Another important aspect that contributes to uncertainty in drug load estimates,
and is often overlooked, is the sampling procedure.
Sampling for representative substance loads
Unfortunately, we must accept that no measurement is ever exact. Flowmeters
are inaccurate, automatic sampling devices have individual characteristics and
uncertainties linked to sampling time and spatial scales inﬂuence the result. In
addition to validating mass spectrometry techniques, it is necessary to investigate the
representativeness of the measured wastewater pollutant loads.
In urban drainage, discharge is usually measured by an area–velocity method,
which determines the water level (or cross-sectional area) and mean velocity in
the cross-section. Experiments show that, even under optimal conditions, relative
uncertainties are about 20% for ﬂow rates in sewers and 6–10% for wastewater
volumes (Bertrand-Krajewski et al., 2003). For conventional pollutant loads, which
combine ﬂow and concentration measurements, (particles and organic matter),
random uncertainty estimates can be in the order of 25–50% (Gromaire and
Chebbo, 2001; Bertrand-Krajewski et al., 2003), depending on the temporal
occurrence of the substance. More problematic are systematic deviations of
discharge measurement devices. Unfortunately, these are often not detected in
WWTPs, as costly control studies would be necessary. However, such control studies
have been carried out in Germany (Port, 1994) and Switzerland (Thomann, 2002).
These studies revealed that systematic under- or overestimations of ﬂow rates of
about 20% occurred in about 30% of the plants investigated.
To investigate the representativeness of sampling for micropollutant loads in sewers,
Ort and Gujer (2006) presented a concept that makes it possible to quantify the
expected uncertainty for a given combination of substance pattern and sampling
scheme. Substances tested included benzotriazole, a component of dishwasher
powders, and ammonia. As expected, the error was largest for substances that occur
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
N
o
v
0
7
,
2
0
0
8
1
0
:
4
5
:
2
3
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
65
Chapter 4: On the occurrence and fate of illicit substances in sewer systems
in only a low number of wastewater discharges (e.g. from dishwashers) and which
are sampled at low frequency. In addition, the authors estimated the extent to which
error could be reduced by using composite sampling rather than grab sampling.
As the pollutant pattern depends not only on human activity, but also on the sewer
transport characteristics, the impact of the sampling scheme has to be evaluated
for each sampling station individually. Rieckermann and Christakos (2007) adapted
this framework to investigate the sampling error for cocaine loads in a catchment of
4 000 inhabitants, where the average ﬂow distance was 2.5 km (Figure 4). Using a
stochastic simulation model, they estimated that the relative error (ratio of sampled
load to true load) was as high as 7% (single standard deviation) for a 24-hour
composite sample that was based on a 5-minute sampling interval. For a 24-hour
composite sample based on a 20-minute sampling interval, the relative error
increased to 26%.
In the case of larger catchments including a larger number of drug users and
increased dispersion due to longer travel times, the error is expected to be lower,
but currently no rule of thumb is available and stochastic simulations are
recommended to assess the uncertainty on a case-by-case basis.
One important characteristic of sewer systems is that they are buried in the ground.
This not only makes the monitoring of illicit drugs very costly, but also has other
unpleasant repercussions. First, because sewers are a hazardous environment and,
as is the case with all conﬁned spaces, must be tested before entry, experimentation
is relatively difﬁcult (see below) and monitoring studies are not readily performed.
Figure 4: Modelled section of cocaine loads and sampling intervals of 5 minutes (grey) and
20 minutes (black) (from Rieckermann and Christakos, 2007).
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
N
o
v
0
7
,
2
0
0
8
1
0
:
4
5
:
2
4
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
Assessing illicit drugs in wastewater
66
Furthermore, manholes are often located in roadways, which makes them difﬁcult
to access, and a power supply for monitoring devices is usually not available.
Ideally, measuring would be carried out on inﬂuents to WWTPs; however, sampling
performed at the WWTP after initial clariﬁcation would have the advantage that
short-term ﬂuctuations in illicit substances would be largely attenuated by mixing in
the tank and thus the error attributable to sampling frequency would be less critical.
However, as described above, sorption to primary sludge might have to be taken
into account.
Conclusions
Estimating drug loads from wastewater measurements seems a very attractive
concept. However, from an environmental engineering standpoint, both the
back-calculation of consumption ﬁgures and the monitoring of trends from illicit
substance loads have several pitfalls: they require not only information on drug
metabolism and socio-economic usage characteristics, but also an understanding of
the wastewater system and the processes involved. This chapter provided a broad
overview over the urban drainage system and the processes involved, and presented
available knowledge regarding the monitoring and modelling of illicit drug loads in
sewers. As this is an emerging ﬁeld and no experimental data are available, ﬁndings
from comparable studies of pharmaceuticals, which are also present in wastewater
at trace concentrations and have similar characteristics, e.g. hydrophilicity, and are
metabolised over similar time scales, were reported, where appropriate.
Sewer systems are complex and are composed of many different elements. They
have usually evolved over time and are rarely planned from scratch.
As ﬂood protection is mandatory, there is generally a good understanding of
volume ﬂows and substance transport. Critical aspects are the loss of wastewater
due to sewer leakage and the fact that the processes involved are not currently well
understood. Current estimates of loss range from 0 to 20% of dry weather ﬂow or
more, but no generally valid estimates are available.
The interplay of physical, chemical and biological transformation processes
of solutes is not trivial and their understanding is still incomplete, even in the case
of conventional pollutants. There is some evidence for transformation of illicit drugs
in sewers, but very few experimental data have as yet been published. Research on
pharmaceuticals and personal care products suggests that the processes that might
affect cocaine and its metabolites are biotransformation and (to a lesser extent)
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sorption in sewer bioﬁlms and sediments. However, little experimental evidence
of the magnitude of these processes in WWTPs is available and to date there are
no experimental data are available regarding these processes in sewers. It has still
to be proven whether drug loads are inﬂuenced by natural processes (e.g. seasonal
variations due to changes in wastewater temperature).
The back-calculation of prevalence levels requires accurate analytical measurements
with reliable estimates of uncertainty. In addition to analytical uncertainty, the
sampling uncertainty also has to be taken into account. To date, no rule of thumb is
available for this task, and stochastic simulations are recommended to evaluate the
representativeness on a case-by-case basis.
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Disease mapping
Maps have been used in medical geography for almost 300 years, although disease
mapping did not become widespread until the nineteenth century, when health data
became available, accompanied by the desire to evaluate geographical patterns of
diseases and to identify risk factors that might affect such patterns. Maps were used
by statisticians, medical doctors and geographers to test many theories of causation.
The most famous map at the time was that made by John Snow in 1854 to study the
distribution of cholera in England. His map was an important step in determining the
causal relationship between disease and place and strongly inﬂuenced subsequent
mapping of diseases and health. For many years, the main purpose of maps was to
depict features of the real world or to present the results of statistical analysis, but
they also acted as a communication tool for disseminating information.
Since the development of new geotechnologies, especially geographical information
systems (GIS), in the last three decades of the twentieth century, maps have become
much more than just a means of transmitting knowledge; rather they are now a
means of generating new knowledge. Maps are now viewed by health scientists
as an important tool to better understand the relation between humans, disease
and the environment. Mapping ranks with other tools of spatial statistical analysis,
epidemiology and public health in helping to further our understanding of the nature
of health events (Koch, 2005).
Geographical information systems
GIS provides a set of sophisticated options for spatial analysis. Within a GIS it is
possible to overlay different maps to visualise complex topological relationships
such as connectivity, proximity and adjacency and to identify inﬂuencing factors
or how these change between different areas. This can be of particular use in
the context of sewage epidemiology. First, it is possible to overlay maps of the
sewage network on maps showing population distribution derived from census
data, enabling the demographic characteristics of the population to be linked to the
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wastewater system. Census data include the number of people of each gender and
in different age groups as well as some types of socio-economic information. This
background information will improve estimates of consumption based on drug loads
in wastewater. The data link allows estimates to be broken down by sex, age or
socio-economic conditions.
In addition, by considering each wastewater system as a discrete unit, the use
of socio-economic information will enable comparisons between geographic
regions. The geographical unit of analysis, in this context, is the area served by the
wastewater system, which can be an entire city, part of a city or a city plus some
area extending beyond the city limits. In practice, it is quite common for several
municipalities to share complex wastewater systems.
As population data obtained from censuses are associated with administrative areas
[census tracts, municipalities, districts or NUTS (nomenclature of territorial units for
statistics) regions], rather than the area served by a sewage system, GIS are a useful
means of interpolating the population of the area of interest with the area served by
the wastewater system.
Besides the precise identiﬁcation of the population linked to the sewage system,
it is also possible to model the concentrations of certain drugs coming from
speciﬁed treatment facilities within the geographical region under focus and, if
monitored continuously, to detect any reduction in drug use resulting from a speciﬁc
intervention programme. Ideally, samples should be collected from more than one
site in the sewage system, in order to identify differences in consumption, while at
all times maintaining conﬁdentiality. By mapping the sources of high concentrations
of speciﬁc drugs and relating these to the population at risk, it is possible to
suggest hypotheses for further investigation. The use of GIS enables environmental,
socio-economic and health data to be combined, improving analytical output and
inferential statistical methods.
Mapping and statistics
In the context of analysing the spatial distribution of an event, maps should be
used in conjunction with statistical tools to describe, compare and interpret results.
Descriptive or inferential statistics help to make explicit what is implicit in maps.
Statistics add precision to a qualitative description, facilitate comparisons between
different populations in time or space and reveal details that are not apparent in
more qualitative analyses.
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Applied statistics have three important advantages:
they enable spatial data to be collected systematically;•
they enable analysis and visualisation of data in the form of maps•
or summary measures;
they enable conclusions about the generation of data to be extracted•
from probabilistic models (Assunção, 2001).
Statistical tools can be used to draw inferences about drug consumption based
on observed data from samples. The classic approach aims to determine what
generalisations (if any) can be made about a population based on samples collected
from that population. The Bayesian approach considers that spatial correlation or
other ‘random effects’ may be modelled using prior distributions. Prior distributions
can be constructed from the knowledge of specialists or empirically from the data
(Paulino et al., 2003). The spatial statistics approach can be deﬁned as the set of
scientiﬁc methods that are used to collect, describe, visualise and analyse data in
a geographic context. In broad terms, ‘spatial statistical analysis is the quantitative
study of phenomena that are located in space’ (Bailey and Gatrell, 1995). The main
difference from non-spatial analysis is that the place where the event occurs is,
in an explicit way, present in the analysis (Assunção, 2001). Spatial analyses are
based on the ﬁrst law of geography, deﬁned by Waldo Tobler in 1970, who stated,
that ‘everything is related to everything else, but near things are more related than
distant things’.
Data categories
There are four categories of geographic data, and in each case a set of statistical
techniques is available to perform analyses.
A point data set consists of a series of point locations with coordinates that
represent the exact site of events. In the case of sewage epidemiology, each point
is the location of one sample captured in the wastewater system. Point pattern
analysis focuses on observed random patterns or some form of regularity
(Bailey, 2001). Analyses include kernel estimation or smoothing, distance methods,
K-functions, multiple types of events, bivariate K-functions and space–time clustering.
Spatially continuous data include a set of point locations in the region of study.
However, these data are different, in so far as the focus is not on the exact location,
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but seeks to explain observed variation in an attribute value over the region
(Bailey and Gatrell, 1995). Thus, the focus of this method is centred on the surface
of the phenomenon under study, rather than the location (Assunção, 2001).
Analyses of this type include trend surface, variograms and covariograms, spatial
regression, spatial prediction and Kriging.
Area data consist of variables associated to polygons and are commonly used to ﬁnd
spatial trends in attributes, trying to ‘explain’ spatial variation within the attributes of
the variable of interest in terms of covariates measured (Bailey and Gatrell, 1995).
In addition, the technique aims to detect subareas, where the values are higher than
expected, according to an applied statistical method. These objectives are particularly
important in demographic studies and those analysing health, political or economical
activities. The focus of this process is in the spatial distribution of the attributes
through the areas. This would include smoothing methods, kernel regression, spatial
correlation, correlograms and spatial regression.
Spatial interaction data are of particular relevance to the study of emerging
diseases. Spatial interaction models analyse and predict the movements of people,
information and goods from place to place. Spatial modelling and mapping
of geographical interactions is best represented by ﬂow patterns, e.g. the ﬂow of
the number of people, goods or services between their origin and their destination
(Assunção, 2001). The resulting maps are called ﬂux maps. The use of this kind
of data in the context of this approach enables the analysis of distribution patterns
of substances in a wastewater system as well as the creation of ﬂux maps in a
greater geographical context when monitoring various plants within a country.
These four categories of spatial data allow a variety of spatial problems to be
solved. Although area data are the most widely used in health studies, they are not
always the best analytical approach to visualise a geographic phenomenon. When
aggregating data into areas, it is assumed that each area is homogeneous and that
differences between areas occur discretely at the borders. This is not true either
for diseases or for any other geographical variable that is non-linearly distributed.
Populations tend to concentrate in certain areas and demographic density changes
smoothly from one neighbourhood to another. Surfaces are considered a more
natural way to analyse and represent the underlying distribution of population data.
There are many methods to construct such surfaces, all of them being based on
the construction of a grid of regular cells, each of which has an associated value.
The value of each cell is interpolated from the sample points (for instance, one point
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localised in the centroid of a NUT3 (1) area, with the value of a variable for the
entire area artiﬁcially associated with that point). The closer the sample points are
to a cell, the greater their contribution of the ﬁnal value of that cell.
There are several mathematical algorithms that can be used for interpolation, but all
of them are based on this basic principle of spatial analyses — the closer, the more
likely. The value of each cell is calculated as a function of the closest sample points.
How many and which points contribute to each cell depend on a moving window
(called bandwidth) that is based on each sample point, and with a radius of search
for sample points that is deﬁned by the user. This parameter determines the amount
of smoothing, because it deﬁnes the region of inﬂuence. A very large bandwidth will
produce a ﬂat surface and local features may be obscured; in contrast, a very small
bandwidth will produce a very spiky surface, with ‘peaks’ in every sample point.
A method that is often used to generate surfaces is kernel estimation, which is an
estimate of the intensity at events per unit area (Bailey and Gatrell, 1995). Another
problem when dealing with data associated with areas in health studies is the
well-known ‘problem of small numbers’, which occurs when calculating rates in areas
with small populations. A small increase in the numerator results in a large increase
in the rates that does not represent a real increase in risk. As a consequence of this
statistical instability, the rates may not be reliable and may merely reﬂect random
ﬂuctuation. Such problems are common when working with political administrative
areas in which the range of population at risk varies widely.
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Drug use monitoring
Accurate estimates of drug consumption in a population and of how consumption
has changed over time would be a pillar of evidence-based drug policy and inform
public health, social science and economic models (Reuter and Stevens, 2007;
Thomas et al., 2007). For example, one could monitor whether drug consumption
has fallen or increased in response to a change in the delivery or coverage of
interventions. In the United Kingdom and other European countries, there have
been substantial increases in the number of people in opioid substitution therapy,
yet despite clear evidence of effectiveness at the individual level it is unclear what
impact this has had on heroin consumption in the population at large.
Currently, accurate estimates of drug consumption are unavailable, as a
consequence of the usually stigmatised nature of drug use, which often leads drug
users to hide their habits. This inﬂuences data quality to a potentially large extent.
Drug monitoring systems rely heavily on unknown rates of willingness to self-report
use and to participate in general population studies, or to become ‘visible’ in routine
statistics as a result of contact with services and institutions such as drug treatment
services, police, hospitals and other medical or social services.
However, the joint interpretation of the available prevalence and incidence
indicators, in combination with other drug-related indicators such as drug treatment
demand, drug-related infectious diseases, drug-related mortality and drug supply
data, has so far permitted a relatively global but broad monitoring of prevalence
and incidence, patterns of use and trends over time in the European Union
(EMCDDA, 2007).
In this chapter, we give a brief description of current methods for monitoring and
estimating drug use as well as a discussion on some aspects that may need further
review for linking prevalence estimates based on wastewater with those based on
established methods.
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Prevalence estimation methods
There are two principal methods of prevalence estimation: ‘direct’ estimation through
general population surveys, including more targeted surveys such as school surveys,
and ‘indirect’ estimation methods that are based on extrapolating from the observed
parts (e.g. problem drug users in treatment) of the target group to be estimated
(e.g. problem drug users).
Direct methods
General population surveys directly measure the prevalence of drug use in a
sample that is assumed to be representative of the general population, as prevalence
is directly inferred from the proportion in the sample giving a positive answer,
with or without some correction for staged or stratiﬁed sampling. Although the
methods are easy to understand and often appealing because of their conceptual
simplicity, estimating the prevalence of drug use patterns adopted by very small
proportions of the general population or estimating prevalence of very severe
patterns of use, such as heavy use, injecting drug use or problem drug use (PDU),
may be highly problematic.
This is ﬁrst a problem of precision (reliability). In the case of drug use patterns
that affect only a few individuals per 1 000 population, very large sample sizes
are required to gather sufﬁcient cases for reliable prevalence estimation.
Second, there are problems around the potential bias (validity) of the method
arising from the fact that the inclusion of homeless or otherwise deviant people in
the sampling frame is likely to be insufﬁcient. For example, if a sizeable proportion
of heroin users are homeless or unable or unwilling to respond to a request to
participate in a general population survey, then even very large samples will fail to
provide reliable data. A third problem with general population surveys
is caused by the already mentioned stigma and prejudice associated with heavy
patterns of use in many societies, causing potential participants to choose not
to disclose their heavier drug use patterns. It is not possible without supplementary
studies to know the extent to which those who are interviewed are not telling
the truth for fear of stigma or other consequences or, conversely, perhaps
overstating drug consumption in order to ﬁt with social norms in their peer group
(e.g. male schoolchildren).
For example, in a randomised general population survey experiment in the USA,
respondents were more likely to report the recent use of ‘harder’ drugs in a
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telephone-based audio-computerised interview (T-ACASI) than to admit this to human
interviewers. T-ACASI respondents were more likely to report cannabis use in the
past month (10.0% vs. 5.7%, crude odds ratio (OR) = 1.9, P < 0.001), cocaine use in
the past month (2.1% vs. 0.7%, crude OR 3.2, P < 0.001) and injection drug use in
the past ﬁve years (1.6% vs. 0.3%, crude OR = 4.8, P < 0.01) (Turner et al., 2005). In
another general population survey in the USA, in which respondents were asked to
give a hair, saliva and urine sample immediately after a computer-assisted interview
in their home, under-reporting appeared to depend both on the drugs reported and
on race (probably as an indicator for social factors): ‘… higher rates of cannabis use
were generated from survey reports than from drug testing. Drug testing generated
higher prevalence rates than survey reports for recent use of cocaine and heroin.
Under-reporting of recent drug use was apparent for all three substances. Sensitivity
was particularly low for cocaine and heroin. Race was related to under-reporting,
with African Americans less likely to report cannabis use despite a positive test
result’ (Fendrich et al., 2004).
The problems with general population surveys are probably less severe when
looking at drugs whose use is more prevalent, for example, cannabis or ecstasy and
in some countries perhaps also powder cocaine, if one assumes that heavy users
missed by the general population survey constitute a relatively smaller proportion
of the total owing to the generally higher overall prevalence (as a result of larger
numbers of ‘light’ users). However, the problem of relying on general population
surveys alone can be severe in the case of drugs or drug use patterns that usually
involve only a very small proportion of the general population, typically opioid
use or injection and crack use, and in some countries also the heavy use of
amphetamine, methamphetamine or powder cocaine.
Indirect methods
Thus, in drug monitoring systems, the use of general population surveys needs to
be complemented by ‘indirect methods’ for estimating the prevalence of heavier
patterns of drug use such as heroin use, crack cocaine use, amphetamine use,
injecting drug use or more in general ‘problem drug use’ (PDU). Of these indirect
methods or PDU estimation methods, some have been used more consistently in
several countries, following the initial development of consensus guidelines in the EU
(EMCDDA, 1999, 2004; Kraus et al., 2003) that have subsequently been adopted for
use in other parts of the world (UNAIDS/WHO, 2003; UNODC, 2003).
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The indirect methods include:
multiplier-benchmark methods that basically multiply observed cases by a simple,•
independently obtained, multiplier value;
capture–recapture methods, which estimate prevalence from observed double-•
counts between multiple datasets and which can in the best case adjust for some
of the dependencies between those datasets;
the multivariate indicator method, which extrapolates from existing local•
prevalence estimates to a larger (national) geographical level;
some less commonly used approaches that may require more assumptions•
but have in some cases been successfully applied (e.g. demographic method,
truncated Poisson method).
In general, these methods estimate the total number of drug users that are
comparable, in terms of likelihood of being observed in the different statistics,
to the actually observed cases in routine statistics or samples. They are called
‘indirect’ methods because, rather than estimating prevalence ‘directly’ in a general
population sample (prevalence is simply the observed percentage of cases in
the sample) and then accounting for the known ‘sampling intensity’ of the study
(proportion of the sample among the total population) to estimate the absolute
number of cases in the population, they ﬁrst estimate the sampling intensity of the
observed cases (estimate what is the proportion of observed versus non-observed
cases), after which a population prevalence is obtained by dividing the estimated
total existing cases by the size of the general population in the same area.
The fact that drug users have to be comparable to those observed in routine statistics
means that drug users who have not developed the type of behaviour that would
lead them to come into contact with the sources of those statistics (e.g. police,
hospitals, drug treatment centres) are not estimated and remain hidden, even from
the ﬁnal (PDU) estimates. This is not a problem in so far as these individuals can be
assumed not to be problem drug users. However, problem drug users who have a
lower probability of being ‘caught’ by routine statistics (for example, women whose
partners buy drugs for them and who are thus less likely to be caught by the police)
can be accounted for only by assuming that these users are few, such as is probably
the case for the drugs included in the EMCDDA deﬁnition of PDU (opioids, cocaine
or amphetamines). For example, if one assumes that a heavy user is very likely to
come in contact with these institutions, then it follows logically that what is not being
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estimated is mostly non-heavy (non-dependent, non-problematic) use. The non-heavy
users are then either users who will develop problem use in the future (as part of
their drug-using ‘career’, these users will possibly be counted in future estimates) or
users who will never do so and will always remain hidden from PDU estimates
(and are best estimated using general population survey given their likely higher
numbers and likely less problematic or deviant lifestyles).
The EMCDDA uses a rather global deﬁnition for problem drug use (‘injecting
drug use or long duration/regular use of opioids, cocaine and/or amphetamines’)
that is not directly related to existing classiﬁcations of abuse and dependence
(DSM) or harmful use and dependence (ICD), which require exact diagnosis by
an experienced physician. The EMCDDA deﬁnition of PDU rather follows from the
indirect methods used to estimate PDU, i.e. by selecting data sources for using the
indirect methods that probably contain the target group of problem drug users and
by selecting according to the agreed drugs within those sources (e.g. excluding
cannabis users from drug treatment data) it is assumed that the resulting PDU
estimate reﬂects reasonably well the group of users who are ‘problematic’. Note
also that the deﬁnition of PDU does not mention ‘problems’; rather, it assumes that
a harmful route of administration (‘injecting’) and ‘long duration/regular’ use of
certain drugs are the categories most likely to include the most problematic users
and to exclude non-problem users, although empirical data regarding the sensitivity
and speciﬁcity of the deﬁnition are not available due to the lack of a gold standard
for comparison. In practice, the EMCDDA’s deﬁnition of PDU has worked well to
describe PDU prevalence and incidence at the population level, in the context of a
general lack of precision of PDU estimates and a lack of exact information on the
patterns of use of the target population that can be obtained through these methods.
As is the case for general population surveys, PDU estimates have important
limitations that often preclude deriving very exact or valid information on the
prevalence of PDU. Indirect estimates often depend on a number of assumptions that
are difﬁcult to verify. The assumptions for capture–recapture for example include:
(1) independence of lists; (2) homogeneity of capture probabilities; (3) error-free
matching across lists; (4) no in- or out-migration; (5) no duplicates within a list; and
(6) lists are random samples (Asher, 2002). Similarly, most indirect (and direct)
methods assume that the population is closed (no in- or out-migration) during the
period of assessment (usually several months but often up to one calendar year) and
the effect of in- and out-migration on the ﬁnal estimate is not always clear or even
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discussed, although in some situations violation of this assumption may result not in
bias but only in loss of precision (Kendall, 1999).
The ﬁnal estimates are as good as the data that they are based on, which is often
not as good as would be liked. Problems related to the above assumptions often
follow from the quality of the data available from routine statistics; although this
can be improved by prospective designs (Bello and Chêne, 1997), perhaps even
by using a speciﬁcally designed community-wide recruitment study as one of the
data sources for the estimation. Problems may also stem from geographical and
other sources of heterogeneity in the available data, which prohibit straightforward
interpretation of resulting estimates (validity problems) as well as large uncertainty
intervals around estimates (reliability problems) or the impossibility of producing
conﬁdence intervals at all. For example, the multivariate indicator (MIM) method is
based on an imputation using regression analysis from existing local estimates and
the methodology to incorporate the uncertainty of the local estimates into the overall
MIM estimate is still in development (Frischer et al., 2001; Smit et al., 2006).
In practice, given the nature of the indirect methods and the sometimes low
quality of the routine statistics they use, it may be difﬁcult to know exactly what
types of drug use the problem drug use estimates refer to. For example, consider
capture–recapture estimates based on data obtained from drug treatment, police
and hospital sources. The data from drug treatment and hospitals may be accurate
in terms of the main drugs used, but police data are often not very precise (being
limited to the recording of suspects as ‘drug users’). It is usually unclear to what
extent the resulting ﬁnal estimate of PDU based on these three sources is affected
by the lack of precision on drug use patterns in the police data, and it is likely that
the deﬁnition of PDU of the ﬁnal estimate is as good as the broadest (least precise)
deﬁnition in the original data sources.
As general population surveys and PDU estimates adopt complementary
approaches, they should be used as complementary elements within an overarching
drug monitoring system. Either of the approaches is likely to miss an important part
of the population using a given drug. This implies that both approaches should
be used to estimate total drug consumption, ideally implemented at the same time
and in the same geographic area, compared and checked for consistency. To then
make the next comparison of central interest to this report, that between prevalence
estimates from direct and indirect methods and those based on wastewater
measurements, information on per capita consumption is needed.
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(1) See the EMCDDA deﬁnition above, broadly covering abuse or harmful use of, or
dependence on, opioids, cocaine or amphetamines.
Drug use patterns and the inﬂuence on total consumption
Drug consumption estimates are often based on a combination of the estimated
prevalence of opioid, cocaine or cannabis use and estimates of the pattern and
frequency of drug use by drug users. Consumption is sometimes differentiated into
‘heavy or dependent’ and ‘light or recreational’, based on the average frequency
of drug use. These separate estimates of prevalence and mean use are generated
through a mixture of direct and indirect methods and behavioural surveys — each
with its own uncertainty. These uncertainties will be propagated and may well be
increased through combination.
Information on per capita consumption (including patterns, frequency of use,
average dose) is probably best obtained by targeted surveys directed to recent users
of the drugs in question. This can be done in convenience samples from settings
where these users can be found (e.g. drug treatment centres or low-threshold
centres), but a better approach would be to sample users by chain referral methods
(snowball sampling) (Taylor et al., 2005). One chain referral method much discussed
recently is respondent-driven sampling, in which each respondent is paid to recruit
another respondent (Abdul-Quader et al., 2006a,b).
What remains unknown, and probably varies between countries, is the proportion
of the population using a certain drug who can be classiﬁed as light or recreational
(‘infrequent’) users or heavy (‘intensive’) or ‘problem drug users’ (1). It should be
noted that such a classiﬁcation is still in development at the EMCDDA, although
systems exist in the USA (DSM IV) and at international level (ICD-10) (Hasin et al.,
2006; Saunders, 2006). Also, it is important to note that the possible classiﬁcations
used in Europe (and other regions) are not necessarily one-dimensional, focusing
on time since last use, frequency of use, dependence (SDS or CAST scales, DSM)
or harmful use (IDC-10) or the non-clinical but epidemiologically useful EMCDDA
deﬁnition of problem drug use given above, which is applied to the PDU estimates
resulting from the indirect methods.
For the purpose of this report, a simple division into ‘light’ and ‘heavy’ users would
be useful. This could perhaps be based on frequency of use with a cut-off point of,
for example, ‘using two days per week or less’ for the ﬁrst category and without
necessarily looking at other dimensions such as dependence, harms or problem use.
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As the most interesting parameter for comparing with wastewater measurements
is the total amount used, and given the difﬁculty of determining average dosage
or dosage distribution and patterns (e.g. by day of the week and time of the day),
frequency of use perhaps comes closest to approximating the central parameter
of interest: ‘total amount used over a given time period’. However, an additional
difﬁculty in using this measure is that frequency of use may be quite irregular,
for example it is known that ‘binge’ use of stimulants such as cocaine or
amphetamine is relatively common (2).
The adoption of a simple binary categorisation into light and heavy users raises the
question of whether it is legitimate to estimate the prevalence of both groups in a
study area, to multiply these by a calculated ‘average dose’ and to take the total as
an estimate of total amount consumed in the study area over a given period of time.
As discussed above, it is likely that general population surveys are more powerful
in estimating the prevalence of the light users, whereas indirect methods are
probably needed to estimate the number of heavy users. It is difﬁcult to estimate the
proportion of the total consumption accounted for by light and heavy users, but this
is important to enable the sensitivity of total estimated drug consumption to direct
or indirect methods used. Such knowledge would perhaps enable the calculation
of a conﬁdence interval taking account of uncertainties in data obtained by both
the general population survey and indirect methods, and perhaps resulting in one
of the estimation methods being omitted because its contribution to total use would
be too small to be of interest. However, it is not easy to determine in advance if the
total amount used is inﬂuenced more by a larger group of light users or by a smaller
group of heavy users.
To combine these different types of information, a conceptual and/or mathematical
model should be constructed. There is often a lack of an appropriate framework to
combine multiple information sources and test their consistency in order to validate
their output. Indirect prevalence estimates, for example, are often unreliable and
open to bias because they rely on numerous, potentially erroneous, assumptions
(as discussed above). Equally, estimates of drug use frequency and dosage are
open to bias arising from the difﬁculty of generating representative samples of drug
users. Evidence synthesis methods utilising Bayes’s theorem offer the opportunity of
testing the consistency of information (Ades and Sutton, 2006). Speciﬁc examples
(2) Not using for long periods and then suddenly using at very high frequency over several
consecutive days and nights.
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in the drugs ﬁeld include estimates of the prevalence and number of HIV and HCV
infections, which have been used to derive and test estimates of the prevalence of
current and former intravenous drug use and the prevalence of HIV or HCV by risk
group based on multiple information sources (Goubar et al. 2006; Sweeting et al.,
2008). Information on drug consumption derived from metabolite testing within an
‘evidence synthesis’ framework would allow improved estimation of the prevalence of
different types of drug use and frequency of use.
The problem with this type of estimation of drug consumption is twofold. First,
information that would enable testing the reliability or consistency of estimates of
total consumption, drug use prevalence and frequency are not available. In theory,
estimates of drug seizures or drug importations and production could be used to
produce a model of consumption against which consumption and use estimates
could be validated. However, the relationship between these data and the true level
of consumption is also uncertain, inﬂuenced as it is by changes in policing and
interdiction policy, and is therefore unlikely to be informative. In contrast, it is likely
that metabolite testing, as outlined in the case study and discussion below, could
provide an accurate measure of overall drug consumption and thus constitute a data
source that could inform and test the consistency of combined information on drug
prevalence and frequency of use, within an appropriate framework model.
Can prevalence be estimated and compared using wastewater data?
As mentioned elsewhere in this document, a number of additional uncertainties
complicate matters when comparing prevalence estimates using ‘wastewater data’.
First, it is difﬁcult to determine whether a change in, for example, cocaine ﬂow
through the system is the result of a change in the number of inhabitants using
cocaine or could be explained by people entering or leaving the city. Second, even
assuming a ‘closed city’, it would still be difﬁcult to determine the extent to which
the measured variation reﬂects variation in levels of use (patterns of use, dosage)
or variation in the number of active users (prevalence). Targeted surveys of users
could shed some light on average dose used and patterns of use (e.g. over different
days and hours in the week) at a certain point in time. However, these surveys could
not be used to continuously adjust the measured quantities and thus continuously
adjust the prevalence estimates.
Perhaps a more sound position is to use wastewater measurements not for
continuous prevalence monitoring, but rather for continuously monitoring the
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amounts of a drug in the wastewater system. In this case, the main outcome
variable at city level would be a ‘consumption index’ based on a ‘standard dose’
(an internationally agreed deﬁnition/amount) and the number of ‘standard users’
(assuming that further research conﬁrms that binary classiﬁcation into light and
heavy users can be omitted). However, it seems unlikely that changes in drug residue
concentrations in wastewater will necessarily be directly correlated with changes in
prevalence estimates in any simple way.
Another option is to regard wastewater data as an additional ‘indirect indicator’
of drug use. Although the main part of this contribution has discussed the two
general methods of estimating drug use prevalence, another way to use drugs data
for monitoring is to follow trends over time in so-called indirect indicators, without
generating explicit prevalence estimates, as mentioned in the introduction of this
chapter. Indirect indicators are any statistics that are probably related to drug use
prevalence. Among these would be drug overdose deaths and drug-related cases
of HIV or hepatitis B/C — all likely to be mostly related to injecting drug use; drug
treatment demands — probably related to drug problems in general; drug-related
emergencies — reﬂecting acute problems such as overdose, and police drug seizures.
Although there have been attempts to relate different combinations of indirect drug
indicators to prevalence, no generally accepted model has yet been developed,
mainly because of the lack of comparability of available datasets between countries
and over time (EMCDDA, 2001). Wastewater data might provide a unique and
comparable set of data, as an additional indicator, for improving this situation. It
is thus imperative to invest in the development of better models that can utilise this
important data source in order to test and validate the consistency of estimates.
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Roberto Fanelli and Norbert Frost
Health benchmarking data are often used in epidemiological studies. Public health
surveillance methods are currently used for the systematic collection of data that
can be used for the planning, implementation and evaluation of public health
programmes. Similarly, the collection and analysis of data in relation to speciﬁc
locations are already used with regard to, for example, unemployment rates, road
trafﬁc accidents, air pollution and the quality of bathing water.
Wastewater analysis offers an interesting and new opportunity to provide a
comparable picture of the distribution of illicit drug consumption, which could also
help to inform a more precisely tailored preventive response or other appropriate
interventions. In view of a proposed European agreement to monitor wastewater for
environmental purposes, it may be feasible to consider the possibility of extending
this approach to include monitoring of illicit drugs.
The analysis of illicit drugs in wastewater samples represents a new ﬁeld of study;
one that until recently has not attracted much attention. However, case studies
are now being conducted, and scientiﬁc research in this newly emerging ﬁeld is
progressing quickly. Studies of speciﬁc urban areas with known elevated prevalence
and good quality background data (demographic, socio-economic) could be
particularly interesting and fruitful for further research investigation.
A wastewater system contains information about the society that it serves, and it can
reﬂect the behaviours of that population with regard to its discharge of liquid waste.
Wastewater sampling for drugs in any given area has the potential to provide what
might be regarded as a drug consumption index. This method is most suited for the
purposes of drug surveillance at the community level, where it may be used to help
public health and law enforcement activities.
Table 1 summarises the system of wastewater analysis and how information may be
derived from it. The basic data are the measured concentrations of drug residues in
the wastewater point of sampling (for example, at the inﬂow to the sewage treatment
plant). These data, combined with information on the mass ﬂow of sewage at the
sampling point, enable estimation of the daily amounts of drug residue entering the
wastewater system. At this level, a number of assumptions are required regarding
the processes and events that occur prior to the analysis. The data may, for
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Table 1: Overview of the types of information relating to community drug use
that may be provided by analysis of drug residues in wastewater systems
Information provided Data requirements Notes
Drug residue load
(the amount of drug
passing through the system
in a given time)
(Estimate 1)
Concentration of a drug
residue in wastewater
Flow rate of wastewater at
sampling point — from which
mass ﬂow of water can be
calculated
These are the
initial measurements
Assumptions:
No signiﬁcant loss in
the sewage system
Excretion rates of target drug
residue at population level
Standardised daily amounts
(g/day/1 000 people)
(Estimate 2)
Estimate 1
(drug residues over time)
Population served
by system
Migration activities
within population
Allows tracking of variation
over time in the case of
continuous measurement
Assumptions:
No considerable variation
in population during
measurement intervals
Exclusion of potential
confounders
Total amount of
target drug consumed
by population
Consumption rates
for target population
and variation over time
(Estimate 3)
Estimate 2
(total drug excretion rates for
the population)
Typical excretion rates
Assumptions:
Excretion rates ‘typical’ and
stable for target population
Total number of doses
of target drug consumed
(over monitoring period)
(Estimate 4)
Estimate 3
(total amount of drugs
consumed by target
population)
Information on typical doses
(purity, size etc.) for target
population
Knowledge about typical
doses at street level including
purity is often limited
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example, be affected by leakage from sewers, heavy rainfall or the introduction of
pharmaceutical or chemical agents into the system.
Assuming that there are no losses from the sewage system, the drug residue load
in the wastewater is identical to the amount of drug residue excreted. In a second
stage of the model, the estimate of total drug residue excretion can be translated
into an average daily amount per head of population. The interpretation of this
data will also be affected by the assumptions that are made about the stability of
the population within the catchment area, and whether large events or temporary
changes in population are known to have occurred. A third stage permits a rapid
calculation to be made of the index of drug consumption. At this stage of the
analysis, further interpretation of the results may require assumptions about the
metabolism of the drug in question — and especially about the percentage of
target drug residues that are excreted in relation to the amount of the drug that was
consumed. On the basis of such assumptions, the results may be interpreted in terms
of estimates of the daily amounts of drugs consumed (1).
Assuming that the prior stages of the model have been met, a fourth stage might
allow for estimates to be made that number the doses of the target drug that
are being consumed, or alternatively, of variations in patterns of drug use over
time. Again, interpretation of the data at this stage requires certain assumptions,
for instance, knowledge of typical daily doses of drugs used by recreational or
problematic users, and knowledge about the purity levels of illicit drugs.
It is clear that wastewater sampling as a monitoring tool is still far from being able
to identify drug consumption patterns or categories of users. Instead, it provides
a screening tool for communities. The assessment of illicit drugs that have been
introduced into wastewater systems is not intended (nor very likely to succeed) in
targeting individual drug users. The assessment yields average values of ‘output’
that allow the characterisation of a relatively well-deﬁned entity within a given
geographical area. Any further extrapolation towards prevalence estimation of drug
use will require additional demographic, epidemiological and other information.
The usefulness of the index of drug consumption obtained by monitoring drug
residues in wastewater systems will be greatly increased when this is cross-matched
(1) These areas of uncertainty and the need to make different types of assumptions have
been discussed throughout the text. Some of them are also identiﬁed later in this
concluding chapter as issues for further research investigation.
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with other data sources. As with other indirect estimation methods, the utility of
the results are enhanced by combining them with multiple data sources so that the
additional information can be used to provide greater speciﬁcity and accuracy
of the results. This sort of supplementary information is usually derived by other
methodologies from other sources. Particular attention should be paid to the
potential for using multiple data sources to link the results of wastewater analysis with
ﬁndings from other studies about the characteristics of the target populations and on
geographical issues to enhance the interpretation and application of the results.
It can be seen from the various chapters and discussions in this volume that work
in this area is still at a very early stage. Advances will require further theoretical
development of the key concepts of sewage epidemiology as well as improvements
to the current rudimentary model. In addition, there are undoubtedly many
opportunities to support the development of this approach through well-conducted
empirical research studies. Although the informed reader will be able to propose
many such topics, the following are suggested as providing a basis for further
theoretical, conceptual and empirical investigation:
• internal dynamics of wastewater systems;
• factors relating to possible degradation of substances from origin to sampling point;
• development of methodologies and reasonable strategies for sampling;
• variations in patterns of illicit drug consumption;
• purity of samples of illicit drugs available at the point of sale to users;
• individual differences in pharmacokinetics and excretion rates;
• potential confounding effects due to multiple drug use;
• prospective long-term monitoring in several wastewater systems;
• ethical and privacy issues.
With regard to the last of these suggested topics for further investigation, it is clear
that both the approach and the procedures of wastewater sampling raise a number
of challenging ethical and legal issues. It would be timely to conduct a thorough
review of current and required legislation concerning sampling procedures for this
new approach to illicit drug monitoring. And it is recommended that a full and open
discussion of the ethical and legal issues should be conducted with all stakeholders.
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Overall conclusions
The detection and analysis of drugs and their metabolites in wastewater is a
challenge, but all new methodologies need time for development. Wastewater
analysis for the monitoring of illicit drugs is still at the earliest stage and requires a
great deal of additional information to support the results and the applicability of
this new and promising approach.
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